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ABSTRACT 
 
The conversion of the cellular prion protein PrPC into the infectious isoform (PrPSc) is the key 
event in prion diseases. The physiological role of PrPC remains one of main challenges in prion 
biology, and it is an absolute requirement also for understanding prion diseases. Putative roles 
for PrPC are based on its localization in the central and peripheral nervous systems and on PrPC-
interacting molecules or metal ions through its unstructured N-terminal domain. 
We analysed  the function of the cellular prion protein using structural biology techniques 
aimed to analyze the interaction between PrPC and NCAM and PrPC with copper ions. We first 
focused on the structural determinants responsible for human PrPC (HuPrP) and NCAM 
interaction using Stimulated Emission Depletion (STED) nanoscopy, surface plasma resonance 
(SPR) and NMR spectroscopy approaches. Such structural and biological investigations 
revealed surface interacting epitopes governing the interaction between HuPrP N-terminus and 
the second module of NCAM Fibronectin type-3 domain, providing molecular details about the 
interaction between HuPrP and NCAM Fibronectin domain, and revealed a new role of PrPC N-
terminus as a dynamic and functional element responsible for protein-protein interaction. 
Subsequently, we have investigated the role of copper in prion conversion and susceptibility 
with a special focus on the non-OR copper binding site. The molecular mechanisms of prion 
conversion are still debated. NMR-based studies on HuPrP and MoPrP globular domains have 
identified the β2-α2 loop as important element able to modulate the susceptibility of a given 
species to prion disease. However, recent studies have highlighted also the importance of the N-
terminal region in promoting structural rearrangements to PrPSc. We studied copper coordination 
in the non-OR region of different species including human, sheep, bank vole and opossum. By 
using in vitro approaches, cell-based and computational techniques, we propose two types of 
copper coordination geometries, where the type-1 Cu(II) coordination displays a closed non-OR 
region conformation associated with less-susceptible species, while in type-2 a less structured 
and solvent exposed non-OR region might render the overall PrPC structure more flexible, 
therefore we correlate this with higher susceptibility to prion diseases. Our data highlighted how 
copper coordination in the non-OR copper binding site may explain the different susceptibility 
to prion diseases observed in these mammalian species. 
Ultimately, in the present thesis we expanded our knowledge on how the N-terminus of PrPC 
regulates the physiological functions of PrPC and how it is involved in the prion conversion. 
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CHAPTER I 
 
 
 
INTRODUCTION 
 
 
1.1 Biogenesis of PrPC 
 
The prion protein (PrP) gene (PRNP in human or Prnp in other species) is highly conserved 
among species. The complete open reading frame (ORF) of all known PrP genes is located 
within a single exon [1-3]. In mouse, sheep, cattle, and rat the PrP gene contains three exons 
with the ORF located in exon 3, while human, Syrian hamster, opossum and tammar wallaby 
have 2 exons with the PrP ORF present in exon 2. The other exons contain untranslated 
sequences including the promoter and termination sites. The PrP promoter contains multiple 
copies of GC rich repeats and is devoid of TATA box [4, 5]. In humans, PRNP is a single copy 
gene mapped in the short arm of chromosome 20, which corresponds to the homologous region 
of mouse chromosome 2 where Prnp is located. PrP mRNA has been detected in a wide range of 
tissues and cell types, but the highest concentration is found in the brain, where in situ 
hybridization has demonstrated that the greatest abundance of mRNA is located in neurons [6-
8]. 
As a typical cell-surface glycoprotein, the pre-pro-protein is translocated to the endoplasmic 
reticulum (ER) due to the presence of a 23 amino acids N-terminal signal peptide that is then 
cleaved into the ER lumen. Here, the immature PrP is subjected to several post-translational 
modifications including N-linked glycosylation at residues N181 and N197 of human (Hu), 
formation of a single disulfide bond at position C179 and C214, cleavage of the C-terminal 
signal peptide and subsequent attachment of the glycosylphosphatidyl inositol (GPI) anchor at 
position 231 [9-11]. During co-translational translocation in the ER, PrP can be synthesized with 
three topologies in the ER. The majority of PrP nascent chains generate a secreted form of PrP 
that follow the traditional exocytic pathway to the cell surface. In addition, two C- or N-terminal 
transmembrane forms, denoted as CtmPrP and NtmPrP, respectively, due to transmembrane 
insertion of the PrP hydrophobic domain (residues from 110 to 134) in the ER compartment are 
synthesized [12] (Figure 1.1). The role of the minor forms, CtmPrP and NtmPrP, is still not fully 
clarified but may be associated with neurotoxicity and cellular death especially in case of 
inherited prion diseases [13]. 
The mature GPI-anchored form, PrPC, is derived from the secreted form, which fully 
translocates into the ER and is trafficked through the Golgi apparatus. Here, further processing 
of the N-linked oligosaccharides results in modified glycosylation to complex-type sugar chains. 
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Glycosylation of PrPC is variable, resulting in un-, mono-, or diglycosylated species, depending 
on the number of glycosylation sites occupied with oligosaccharide chains [14]. The mature 
PrPC is found mostly in the cholesterol- and sphingolipid-rich membrane domains, also known 
as lipid rafts, which are detergent-resistant membrane domains with many important cellular 
receptors and other GPI-anchored proteins [15]. Interestingly, the association of PrPC with lipid 
rafts seems to be required for its correct folding, as cholesterol depletion led to its misfolding 
[16-18].  
 
 
 
 
Figure 1.1 Biogenesis of PrPC. The cellular prion protein, PrPC (green coils), is synthesized, folded, and 
glycosylated in the endoplasmic reticulum (ER), where its glycosyl phosphatidylinositol (GPI) anchor is added, 
before further modification in the Golgi complex. Mature PrPC translocates to the outer leaflet of the plasma 
membrane. Instead, CtmPrP and NtmPrP are unusual transmembrane forms, generated in the ER, which have their 
COOH or NH2 terminus in the ER lumen, respectively (modified from [19]). 
 
 
PrPC undergoes cyclic rounds of endocytosis [20] with a transit time of approximately 60 
minutes [21]. The process occurs between the cell surface and the endocytic compartment and it 
can follow either clathrin-dependent pathways, or be mediated by “caveolae-like” domains [20]. 
It was proposed that the N-terminal positively charged motif, KKRPKP, is responsible for the 
endocytosis of PrPC by clathrin-coated vesicles [22]. From the cell surface, PrPC can be 
endocyted to internal endosomal compartments, delivered from early to late endosomes, and 
routed to lysosomes for degradation or recycled to the cell surface for ensuing cycles.  
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1.2 Structural Biology of the Human PrPC 
 
The human PrP (HuPrP) gene encodes a 253 amino acids long pre-pro-protein that is 
subsequently processed as mentioned before. In the mature form, the first 22 residues are 
cleaved after translation, whereas the last 23 amino acid residues are cleaved prior to the 
addition of the GPI anchor to Ser231. The mature human PrPC (HuPrP) is composed of 209 
residues. The majority of high-resolution structural studies on PrPC were carried out with 
bacterially expressed recombinant (rec) PrP, lacking the Asn-linked glycosylation at residues 
181 and 197 [23]. Atomic structures obtained by NMR techniques and X-ray crystallography 
revealed that recPrP shares a very similar fold across different mammalian species [24]. The 
full-length PrPC has a unique structure: while the N-terminal moiety (from residue 23 to 127) 
does not adopt any identifiable folding structure in solution [25], the C-terminus adopts a 
predominantly α-helical conformation with small β-sheet content (residues 128–231) [26]. 
The N-terminus half of the protein may be divided into four different consecutive domains, a 
first charge cluster or CC1, the octapeptide repeat (OR), a second charge cluster or CC2, and a 
hydrophobic domain-termed (HD), containing a palindromic region consisting of an alanine-rich 
tract of amino acids, AGAAAAGA, which is highly conserved across a wide variety of 
mammalian species. CC1 and CC2 (residue 23-27 and 95-110, respectively) seem be involved in 
glycosaminoglycans (GAGs) [27, 28] and nucleic acids [29, 30] binding. It has been observed 
that the CC1 region is involved in recycling and internalizing PrPC from the cell surface [31]. 
However, mice lacking CC1 or CC2 domains did not show pathologies and are susceptible to 
prion infection [32, 33].  
The HD is believed to play a role in the PrPC function in concert with CC2. Indeed, ablation of 
CC2 in combination with a partial or complete deletion of HD causes severe pathologies in 
transgenic (Tg) mice, suffering from ataxia to cerebellar granule cell loss. A partial deletion of 
HD is not toxic [34].  
The palindromic sequence AGAAAGA is also known as “toxic peptide”, because short 
peptides corresponding to this segment form fibrils in solution with β-sheet structure which are 
toxic to cultured mouse hippocampal cells, suggesting that this palindromic sequence may be 
involved in the PrPSc to PrPC conversion [35-37]. During the conversion, the region 
encompassing the CC2 and HD is not accessible to antibodies recognizing this epitope in PrPC 
[38], indicating that this segment undergoes profound conformational changes upon conversion 
to PrPSc. Moreover, antibodies directed against this region effectively halt prion replication in 
ScN2a cells [39]. 
The octapeptide-repeat region (OR) is an evolutionarily conserved motif, where histidine 
and tryptophan residues were found to be essential for the binding of copper and other divalent 
cations. The interaction between PrPC and copper will be discussed in more detailed in section 
1.7.3.  
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Figure 1.2. The structure of cellular prion protein. (A) Schematic illustration of primary PrPC structure. CC1: 
charged cluster 1, CC2: charged cluster 2, HD: hydrophobic domain. (B) Secondary structure of PrPC. Histidine 
residues are highlighted in blue, copper ions in orange.  
 
 
The structured C-terminal domain is composed of three α-helices (α1, α2 and α3) and two very 
short β-strands which form an antiparallel β-sheet (β1 and β2). A third β-sheet strand has been 
recently identified and named β0 [40, 41]. 
Helices α2 and α3 form the bulk of the globular domain and are covalently bridged by a 
disulfide bond between Cys179 and Cys214 (Figure 1.2). The C-terminal NMR structures of 
WT HuPrP obtained at different pH values (4.5, 5.5 and 7.0) show almost identical backbone 
tertiary structures with local differences in flexible regions [25, 42, 43]. 
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1.3  PrPC and prion diseases 
The post-translational conversion of PrPC into the misfolded, pathogenic form, called prion or 
PrPSc, plays a key role in transmissible spongiform encephalopathies (TSEs), or prion diseases. 
Prion diseases are transmissible neurodegenerative disorders affecting human and a wide range 
of animal species. These disorders can arise sporadically, be inherited, or be acquired through 
infection.  
 
1.3.1 Animal prion diseases 
Animal prion diseases include scrapie of sheep, goats and mufflons [44], bovine spongiform 
encephalopathy (BSE) in cow [45], transmissible mink encephalopathy (TME) in ranch-reared 
mink [46], feline spongiform encephalopathy (FSE) in domestic cats [47], chronic wasting 
disease (CWD) of cervids and spongiform encephalopathy of primates [48]. 
Scrapie is the ancient form of TSEs. It occurred in sheep and goats [49]. Neuropathological 
signs are spongiform vacuolation, astrogliosis and the deposition of PrPSc amyloid plaques in the 
central nervous system (CNS). The incubation period of scrapie is 2-5 years and death occurs 
within 2 weeks to 6 months after clinical onset. Several polymorphisms in Prnp have been 
associated to scrapie susceptibility in goat and sheep. For example, Q171R and A136V 
polymorphisms confer resistance and susceptibility to the infection, respectively. This part will 
be discussed in more detailed in section 1.6.2. 
Bovine Spongiform Encephalopathy (BSE) is a fatal neurodegeneration in cattle. The 
pathology presents with tremors, ataxia, aggressive behavior and hyperactivity to stimuli. PrPSc 
accumulation and spongiform vacuolation are usually found in the brain, and the incubation 
period for BSE is 2 to 8 years. Besides the classical BSE (cBSE), in recent years two atypical 
forms of BSE have been identified in several European countries [50], Japan [51, 52], United 
States [53] and Canada [54]. The two atypical BSE strains -denoted as H-type BSE and L-type 
BSE- [55] are identified by the higher and lower electrophoretic mobility of the unglycosylated 
protease resistant PrPSc fragment, respectively [56]. Histopathological as well as immuno-
histochemical analyses show that atypical forms of BSE can be experimentally transmitted to 
transgenic mice and primates and clearly differ from cBSE isolates, with unique incubation 
periods, PrPSc profiles and histological lesions [57, 58].  
CWD is a TSE of captive as well as free-ranging members of the family Cervidae. Since 1967 
CWD has been documented in 24 USA states, 2 Canadian provinces and in imported animals in 
South Korea. Recently, it has also been confirmed 5 cases of CWD in Norway. The affected 
species include mule deer (Odocoileus hemionus) [59], white-tailed deer (O. virginianus) [60], 
Rocky Mountain elk (Cervus elaphus nelsoni) [48], and moose (Alces alces shirasi) [61]. Deer 
and elk with CWD show subtle signs of disease, characterized by weight loss, isolation from the 
herd, hypersalivation and rarely ataxia. The origin of CWD is still unknown, although 
intracerebral transmission of the scrapie agent has been shown to induce the disease in elk. 
Epidemiological and experimental data provide evidence that horizontal transmission of CWD 
can efficiently occur by contact with affected animals or through environmental exposure [60, 
62-65]. Until now, the natural transmission of CWD has not been proved in humans who have 
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been exposed for long to the affected area and consumed venison. Moreover, transgenic mice 
expressing either the human, ovine or bovine PrPC coding frames did not develop the disease 
when inoculated with the CWD agent. 
Transmissible mink encephalopathy (TME) and feline spongiform encephalopathy are very 
rare prion diseases. TME outbreaks have been reported in ranched mink in the United States of 
America (Wisconsin, Idaho and Minnesota) and FSE has been reported in domestic cats and 
captive wild members of the family Felidae in the UK, with a few cases identified in France, 
Australia, Ireland, and Germany. Histopathological analysis of FSE cases revealed spongiform 
degeneration in the brain and spinal cords, with substantial variations in terms of vacuolation 
and PrPSc aggregation profiles depending on the affected species. For these two uncommon 
TSEs, the death occurs after 2-8 weeks of the clinical onset. 
 
1.3.2. Human prion diseases 
In human, TSEs include a heterogeneous group of invariably fatal neurodegenerative diseases 
evenly distributed worldwide and etiologically arising as sporadic, genetic or acquired. 
According to the recent classification, idiopathic forms include sporadic Creutzfeldt-Jakob 
disease (sCJD) [66], sporadic fatal insomnia (sFI) and the variably protease sensitive 
prionopathies (VPSPr). Genetic forms comprise familial CJD (fCJD), Gerstmann-Sträussler-
Scheinker disease (GSS) [67], fatal familial insomnia (FFI) [68] and prion protein cerebral 
amyloid angiopathy (PrP-CAA). The acquired forms are transmitted from human to human, as 
iatrogenic CJD (iCJD) or Kuru [69], from cattle to human, and human to human, as variant CJD 
(vCJD). Sporadic CJD is the most frequent form and accounts for an incidence of about 0.6–1.2 
per million per year [70]. Genetic forms account for 10%–15% of human prion diseases, 
whereas the acquired forms are negligible [71]. Key evidence exists supporting the link between 
mutations in PRNP and genetic prion diseases. Several mutations linked to fCJD, GSS and FFI 
have been identified (Figure 1.3); they display many effects both at the structural and 
pathological levels. Since in genetic prion diseases the conversion process from PrPC to PrPSc 
appears to occur spontaneously in the brain, they represent an invaluable tool for the 
comprehension of the molecular basis of TSEs. 
 
 
 
 
Figure 1.3. Secondary structure of the immature HuPrP with all the currently identified disease-associated 
mutations and polymorphisms (unclassified phenotype in gray; fCJD in black; GSS in red; PrP-CAA underlined; 
FFI in blue; and polymorphisms in green). The mature HuPrP consists of residues 23–231, while the N-terminal and 
α1 α2 α3
Disease-associated 
mutations
Polymorphisms
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C-terminal signal peptides are cleaved during protein maturation. In the lower panel, the frequency of the mutations 
and polymorphisms along the PRNP sequence is represented by colored rectangles (modified from [72]). 
 
It has been proposed that in vitro disease-linked mutations increase the likelihood of 
misfolding by the thermodynamic destabilization of PrPC [73-75], although individual mutations 
differently affect PrPC stability. Mutations may also alter surface properties of PrPC, triggering 
in turn an abnormal interaction with other not yet identified cofactors [76, 77], or causing an 
aberrant trafficking and accumulation inside the cell [78]. 
 
 
1.4 The “protein-only” hypothesis 
 
According to the protein-only hypothesis, the central molecular event in the replication of 
prions is the self-propagating conversion of PrPC to PrPSc [79]. Two different mechanisms have 
been proposed (Figure 1.4). 
The nucleation-polymerization model states that PrPC and PrPSc are at equilibrium, but the 
latter is much less stable, shifting the equilibrium toward the cellular form. Stabilization of PrPC 
occurs only when a stable oligomeric nucleus appears [80]. After this passage, PrPC can adopt 
the scrapie conformation. The rate-limiting step is the formation of the stable nucleus. This step 
of stable nucleus reflects the lag phase of spontaneous conversion and it is accelerated by adding 
preformed PrPSc seeds.  
The template assisted model expects that PrPC can rarely adopt the PrPSc conformer, which is 
more thermodynamically stable but kinetically inaccessible [81]. Whenever PrPSc occurs 
spontaneously or is provided exogenously, it can template the misfolding of PrPC with a direct 
interaction. The rate-limiting state in this model is represented by the dimerization between PrPC 
and PrPSc monomers, or the formation of a less stable folding intermediate denoted PrP*. 
The two models are mutually exclusive; in fact, the nucleation-polymerization model could 
explain the initial formation of the seed, while the template-assisted model could be involved in 
the elongation of fibrils. However, in both cases the formation of oligomeric structures or 
amyloid fibrils represents thermodynamic minima, with respect to PrPC and PrPSc, making this 
process spontaneous. 
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Figure 1.4.	(A) Template-assisted model and (B) nucleation-polymerization model (modified from [26]). 
 
 
1.5 Structural biology of synthetic prions 
 
Determining the structure of prions is of utmost importance in prion biology to understand the 
molecular mechanisms leading to the conversion process whereby α-helical motifs in PrPC are 
replaced by β-sheet secondary structures in PrPSc.  
A defining feature of PrPSc is a high resistance to degradation by proteolytic enzymes such as 
the Proteinase K (PK). Limited proteolysis on PrPSc usually generates a smaller C-terminal PK-
resistant molecule composed by approximately 142 residues starting from residue ~90. 
Historically, PrPSc is denoted also as PrP27-30 because of its electrophoretic mobility, which 
encompasses a molecular weight from 27 to 30 kDa [82]. The protease-resistant core of PrPSc 
has been shown to form aggregates and amyloid, which stain with Congo red and show green-
gold bi-refringence, typical of amyloids [83]. However, it has been shown that the amyloid 
properties of PrPSc are not an obligatory feature of prion diseases [84] and not all PrPSc 
molecules are resistant to protease digestion [85]. 
One feature that distinguishes the two isoforms is their secondary structures. Fourier 
Transform Infrared Spectroscopy (FTIR) and circular dichroism studies have shown that unlike 
PrPC, which is predominantly α-helix (47% α-helix and only 3% β-sheet), PrPSc is mainly β-
sheet enriched [86]. Because PrPSc is insoluble and forms aggregates, the atomic structure of 
PrPSc is still unclear. 
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Over the years, different biochemical and biophysical methods, such as spectroscopy analysis, 
electron microscopy, X-ray fiber diffraction, small-angle X-ray scattering, limited proteolysis, 
hydrogen/deuterium (H/D) exchange, and surface reactivity measurements, have led to several 
three-dimensional (3D) structure structural models of PrPSc. Here the frequently discussed 
models for the structure of PrPSc will be discussed. 
The β-helix model is one of the most popular models that was proposed based on EM data on 
mouse brain-purified PrPSc (Figure 1.5 A). In this model, the prion N-terminal residues (∼89–
175) could get converted into a triangular β-helix containing four turns (four-rung model). In 
addition, they proposed that the β-helix associated with an intact C-terminal α2-α3 bundle, 
which retained its α-helical structure from the PrPC fold [87]. Interestingly, the β-helical motif 
has been observed in other proteins that exhibit biochemical features reminiscent of PrPSc, such 
as partial resistance to protease degradation and aggregation propensity [88]. The fungal prion 
HET-s was shown to form a β-solenoid arrangement of β-sheets that is structurally similar to β-
helices [89]. Remarkably, the C-terminal α-helices that are retained in a previous model are no 
longer supported by experimental data [86, 90]. 
The β-spiral was proposed by Daggett and colleagues based on molecular dynamics 
simulations of PrP conformational fluctuations under amyloidogenic conditions (acidic pH) 
(Figure 1.5 B). In this model, all three α-helices from the original PrP structure were retained, 
while the number of β-strands was extended to four. The model was characterized by a spiraling 
core of extended structure, consisting of three short β-strands (spanning amino acids 116–119, 
129–132 and 160–164) and the recruitment of a nascent β-strand (amino acids 135–140). It was 
proposed that formation of β-strands involves the natively unfolded N-terminal region of PrP27-
30, while the C-terminal α2 and α3 helices remained intact. From individual monomers a 
fibrillary model was build up, in which the β-strands are oriented at angles that are not 
perpendicular to the fibril axis. This model has the highest proportion of α-helical structure from 
all published models and one of the lowest β-sheets contents. Moreover, it does not feature a 
cross-β architecture, known experimentally to be a key characteristic of PrPSc fibrillar 
aggregates. 
Cobb and colleagues proposed a parallel in-register β-sheet model, where the recPrP amyloid 
consists of β-strands and relatively short turns and/or loops with no residual α-helices (Figure 
1.5 C). Furthermore, each molecule of PrP contributes only with 4.8 Å to the length of the 
amyloid fibril. The authors also postulate that the C-terminal region (amino acids 159–219 in 
mouse PrP) is converted to a hairpin structure and that the fibrils are formed as a long two-
layered β-sheet. Although some researchers have adopted this model to explain the structure of 
PrPSc [91], this recPrP amyloid preparation has not been reported to produce infectivity and the 
model does not correlate with the repeating unit size of 19.2 Å observed by X-ray fiber 
diffraction experiments on PrPSc and PrP 27–30 [92].  
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Figure 1.5. (A) The PrPSc monomer and the β-helical model. Residues ~90-175 are shown to form left-handed β-
helices that associate into trimers, leaving the α-2 and α-3 helices of PrPC intact. (B) In the spiral model the two 
native β-sheets elongate in a longer single β-strand, which forms intermolecular β-sheets with other PrPSc 
molecules. (C) Parallel and in-register β-structure model including a continuum of short β-strands from residue ~90 
to the entire C-terminal region (modified from [26]). 
 
 
X-ray diffraction data from both natural and synthetic prions were obtained [93], including the 
Syrian hamster (SHa) Sc237 PrP27-30 strain (SHaSc237), the mouse RML prion (MoRML), the 
mouse adapted synthetic prion (MoSP1), mouse truncated recombinant PrP(89-230) and 
truncated recombinant SHa(90-231) amyloids. Fiber diffraction patterns of SHaSc237, MoRML 
and MoSP1 exhibited a marked intensity maximum at 4.8 Å resolutions, confirming the 
presence of β-strands running perpendicular with respect to filament axis, typical for amyloid 
structures. Equatorial maxima, diminished in intensity with increasing resolution. Equatorial 
diffraction from natural brain isolates and synthetic prions also included an intense, moderately 
sharp, low-angle reflection (63.3 Å), characteristic of fibers with poorly ordered para-crystalline 
packing. These data are more consistent with β-helical model. Contrarily, diffraction patterns 
from both recombinant MoPrP(89-230) and recombinant SHa(90-231) showed a well-defined 
4.8 Å meridional layer line, but with an equatorial broad maximum at 10.5 Å. This diffraction 
pattern is consistent with a stacked β-sheet structure for the major component of recPrP 
amyloids. These differences imply that recPrP fibrils do not have the same amyloid structure as 
A
B
C
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brain adapted prions. This structural information might also explain the substantial differences 
in their infectivity. 
Recently, novel methods to obtain pure preparations of prions from mouse brain were 
developed, showing that pathogenic PrP in these preparations is assembled into rod-like 
assemblies. The infectious PrP rods have a common hierarchical assembly comprising twisted 
pairs of short fibres with repeating substructure [94]. Moreover, cryo-electron microscopy 
studies showed that a four-rung β-solenoid structure as a key feature for the architecture of 
infectious mammalian prions [95] and this feature is present in different infectious prions [96]. 
 
1.6 The species barrier and the prion strains 
 
Transmission of prion diseases between different mammalian species is limited by the so 
called “species barrier” (Pattison IH 1966, Res Vet Sci). The prion species barrier occurs when 
prions from a donor species are transmitted to a different recipient species and can be 
characterize by extended incubation period before the onset of symptoms in the recipient 
species. If prions are then re-isolated from the recipient host and re-transmitted to another host 
of the recipient species, the incubation period decreases and the prions are “adapted”. For 
example, a prion species barrier occurs between mice and hamsters (Figure 1.6 B). Inoculation 
of hamster prions into mice did not elicit disease, nor did it cause an accumulation of PrPSc [97]. 
Samples of PrPSc-negative brain were then passaged one more time into mice, and this again did 
not cause clinical signs for >650 days. However, injection of the mouse brain samples into 
hamsters resulted in rapid lethality. This indicates that the agent had silently replicated for 
several years in mice, but maintained full infection potential towards hamsters. 
The first experimental transmission of a TSE between species was performed with scrapie 
between sheep and goats in 1939, showing 100% susceptibility, suggesting that goats are highly 
susceptible. Then, further experiments were performed with other species to test their 
susceptibility to TSEs. These experiments revealed that some animals such as rabbits and guinea 
pigs display intrinsically very low susceptibility to prion infection [98] in contrast to other 
species such as hamsters and bank voles, which are unusually susceptible [99]. 
Identical animals infected with prions from different sources can develop varying pathologies, 
which upon passage to new hosts of the same species will maintain their biochemical properties 
and clinical outcomes. Infectious prions that present and maintain different pathologies when 
passaged to a new host are referred to as prion "strains" [100] (Figure 1.6 A). 
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Figure 1.6. Prion species barriers and strain variation phenomena. (A) The transmission of different prion isolates 
(prion strain A and prion strain B) to identical hosts results in distinct disease phenotypes, such as incubation times. 
These features persist following serial passages to new hosts. In some cases, strains exhibit characteristic 
biochemical signatures such as electrophoretic mobility of the proteinase-K (PK)-resistant core. (B) Prions isolated 
from one species are often less infectious to other species, as evident by longer incubation times and reduced attack 
rates in these other species. After serial passages, incubation times gradually decrease (adaptation) (modified from 
[100]). 
 
 
Prion strains are the result of alternative stable conformations of PrPSc that can be faithfully 
propagated in new hosts [101, 102]. The differences in these conformations result in differences 
in resistance to PK digestion and electrophoretic mobility after PK digestion [103, 104], varying 
glycosylation patterns [105], sedimentation velocities and resistance to urea and guanidinium 
hydrochloride denaturation [106].  
The combination of different hosts and prion strains can also result in different pathologies and 
clinical symptoms. The most common variation between strains is in the time between 
inoculation and symptom onset, referred to as the incubation period, which is often reproducible 
within hosts of the same species [103, 107]. 
 
1.6.1 Structural variations of PrPC between and within species 
The overall architecture of PrPC shares a very similar fold among mammals. However, 
structural variations among mammalian PrPC are present. Local sequence and structure 
variations are most prominently localized at the interface between the β2-α2 loop (residues 165-
175) and in the C-terminal part of α3 helix (residues 215-228) providing insights into a specific 
PrPC regions that may control susceptibility or resistance to prion conversion. 
A Prion strain B Species barrier 
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The β2-α2 loop region has been identified as important element able to modulate the 
susceptibility of a given species to prion disease [25, 108-112]. 
While this loop is highly flexible in most species, it shows a well-defined conformation in the 
PrP structures of Syrian hamster [113], elk [114], bank vole [115], wallaby [116], rabbit [117] 
and horse [118] (Figure 1.7). 
In the NMR structure of the MoPrP, no resonances could be assigned for the residues of the 
β2-α2 loop, most probably due to conformational heterogeneity of this part of the protein chain 
[119], therefore it is believed to have a flexible β2-α2 loop. In contrast, in the NMR structure of 
PrPC from Syrian hamster, the resonances for the loop residues could be clearly identified; 
residues 166-168 folded into a short 310-helix and amino acids 171-174 formed the first turn of 
α-helix 2 [113]. 
In the structure of elk PrPC, the β2-α2 loop was clearly defined. Elk and deer are species 
susceptible to CWD; they are also quite unique in incorporating a threonine residue at position 
174, which in most known sequences is an asparagine or, less commonly, serine. Mutating two 
residues in the mouse β2-α2 loop to mimic elk PrP resulted in a clearly defined “rigid” loop as 
observed in elk PrP. The great susceptibility of elk to CWD combined with the rigidity of the 
loop in its prion protein led to the hypothesis that structural homogeneity in the β2-α2 loop 
results in increased susceptibility to prion disease [114]. This hypothesis received support from 
an in vivo model in which the rigid loop mutant of mouse PrP was expressed in transgenic mice, 
which subsequently became highly susceptible to prion infection [120]. 
The structure of PrPC from bank voles, a species extremely susceptible to prion diseases, also 
showed the β2-α2 loop in a clearly defined conformation [115], as for the Tammar Wallaby 
PrPC, which also revealed that long-range contacts to the C-terminus of helix-3 may help to 
stabilize the β2-α2 loop [116].  
 
 
Figure 1.7. Backbone fold of residues 162-175 corresponding to the β2-α2 loop the in (A) human PrPC (pdb id 
1QM1), (B) ovine PrPC ARR (pdb id 1Y2S), (C) tammar wallaby (pdb id 2KFI), (D) bank vole PrPC (pdb id 2K56) 
and (E) human PrPC, Q212P) (pdb id 2KUN). 
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Despite growing evidence that rigidity in the β2-α2 loop generally correlates well with 
susceptibility to prion disease there are also some exceptions. PrPC from pigs and rabbits, which 
are quite resistant to infection, also have clearly defined β2-α2 loops [117, 121]. This finding, 
however, can still be accommodated in the framework of the conformational selection model 
when one replaces simple rigidity of the β2-α2 loop with the conformational subset available to 
it as the determinant of resistance and susceptibility. In support of this hypothesis, it has been 
found that amino acid identity at position 170 and its resulting conformational effects are 
determinant to inter-species transmission [122]. 
 
1.6.2. PrPC polymorphisms within species  
There are known polymorphisms in the primary PrPC sequence of different mammalian 
species [123]. In sheep PrPC amino acid polymorphisms at residues 136, 154 and 171 dictate the 
level of susceptibility or resistance to scrapie. For instance, the polymorphisms VRQ (V136, 
R154 and Q171) and ARQ (A136, R154 and Q171) render sheep more susceptible to scrapie, 
while ARR (A136, R154 and R171) and AHQ (A136, H154 and Q171) are considered 
protective polymorphisms [124, 125], although rare instances of infection have been reported 
[126]. During unfolding, all four variants formed an intermediate state rich in β-sheet structure. 
The activation energy for its formation was significantly higher in the resistant variants, ARR 
and AHQ, and accompanied by a lower β-sheet propensity when compared to the susceptible 
variants, VRQ and ARQ [127]. The crystal structures of the OvPrP variants [128] reveals that in 
OvPrP VRQ a hydrogen bond between the Q171 side-chain and residue R167 stabilizes the 
structure, when compared with OvPrP ARR (Figure 1.8). 
 
 
 
Figure 1.8. Comparison of the crystal structure of the globular domain of the ARR allele of sheep PrP (pink, pdb 
id 1Y2S) and VRQ (green, pdb id 1TQB). In the box, the hydrogen bonds between the Q171 side-chain and residue 
R167 is shown. 
 
 
Another case of PrPC amino acidic variations within a species effecting susceptibility to 
infection is the methionine/valine polymorphism at position 129 in the amino acid sequence of 
human PrPC. During the BSE epidemic in the United Kingdom, all documented human cases of 
vCJD have been in individuals homozygous for methionine at residue 129 [129]. The presence 
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of methionine at position 129 results in increased susceptibility to prion disease, while the 
presence of valine at that position appears to be protective [130]. Polymorphism at residue 129 
also modulates the conformational conversion of the D178N variant of human PrP, determining 
the development of either FFI (methionine) or familial CJD (valine) [131]. 
 
 
1.7 Defining the PrPC function 
 
PrPC is a cell surface protein expressed in a variety of different organs and tissues with high 
expression levels. It is mainly known for its role in prion diseases, where its misfolding causes 
fatal neurodegenerative conditions. 
A fully satisfactory understanding of the physiological function of PrPC has been lacking for a 
long time. Putative roles for PrPC are based on its localization in the central and peripheral 
nervous systems and on PrPC-interacting molecules or metal ions [41]. 
 
1.7.1. Insights into the PrPC function from PrPC-null mice 
Soon after PrPSc was proposed to be the causative agent of prion diseases, Prnp knockout mice 
were generated to assess whether the loss of physiological PrPC function would led to 
neurodegeneration in prion diseases. 
The first Prnp null mouse strain, Prnp-/-, or Zurich I, was produced in a mixed C57BL/6J x 
129/Sv(ev) background, by replacing of codon 4–187 with a neomycin phosphotransferase 
expression (neo) cassette [132]. A second line of PrPC-deficient mice, known as Npu or 
Edimburgh (Edbg), was produced by interruption of the Prnp ORF at position 93 and 
introduction of a neo cassette [133]. In a first round of characterization, these mice were not 
found to show any clear abnormality expect for their resistance to prion infection thus proving 
that PrPC is an absolute requirement for developing TSEs. 
In contrast with these earliest lines, PrPC-deficient mice from which the entire Prnp gene was 
removed develop progressive cerebellar ataxia, which initially was attributed to the loss of PrPC, 
since the observed phenotype was abolished by reintroduction of PrPC. [134, 135]. Later, it was 
discovered that this phenotype was due to the deletion of a splice acceptor site in exon 3 of 
Prnp. This led to aberrant overexpression of PrP paralogue gene encoding Doppel (Dpl), 
causing neurodegeneration of cerebellar Purkinje cells. Although ZrchI and Edbg mice did not 
present any obvious physiological abnormalities, these mice lines provided a platform for 
experiments aimed at gaining further insight on the role of PrPC in the context of behavior, 
sleep-wakefulness cycle, memory, synaptic activity and neuronal excitability. 
Immunocytochemical studies showed that PrPC is enriched along axons and in pre- and 
postsynaptic terminals [136, 137] and that it undergoes anterograde and retrograde axonal 
transport. Recently, it has been shown that sialic acid within GPI-anchor is important for 
targeting PrPC to synapses. These observations suggest a role of PrP in preserving normal 
synaptic structure and function by regulating synaptic transmission and plasticity; indeed, 
synaptic dysfunction and synaptic loss are early event in prion diseases [138]. 
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Long-term potentiation (LTP) correlates with synaptic plasticity, which underlies learning and 
memory formation in the hippocampus. Thus, any LTP deficits may results in cognitive defects. 
Even if initial studies did not report any reduction in memory performance in mice Zurich, a 
later study found deficiencies in spatial learning and memory in PrPC-deficient mice. These data 
are in contrast with another study carried out in Prnp ZH1/ZH1 mice that did not reveal any 
memory impairment. Thus, a role for PrPC in memory is still contentious. 
A role of PrPC in sleep homeostasis and sleep continuity has also been proposed [139]. It would 
explain the disruption of sleep occurring in some forms of prion diseases (i.e. sporadic and 
familial fatal insomnia). Nonetheless, the molecular bases of sleep regulation are not completely 
understood. Recent work indicates that calcium-dependent hyperpolarization is critical to sleep 
duration, and that sleep deterioration is associated with impairment of calcium-dependent 
potassium channels, voltage-gated calcium channel (VGCC) and N-methyl-D-aspartate 
(NMDA) glutamate receptors. One of the most detailed functional studies recently published 
deals with the involvement of PrPC and copper ions in NMDAR S-nitrosylation and activity. By 
exploiting PrP knockout mice, the authors showed that the depletion of PrPC is associated with a 
reduction in the S-nitrosylation of the 2 NMDAR subunits GluN2A and GluN1, while not 
affecting the levels of the corresponding proteins at the synapse [41, 140].  
 
1.7.2. PrPC functions suggested by interaction partners 
To gain deep insight into the function of PrPC many proteins that interact and bind to PrPC 
have been identified. Most of them have been identified as potential PrPC-binding partners by 
using many different methods, such as yeast two-hybrid screening, co-immunoprecipitation and 
cross-linking. The functional relevance of the binding has been proved only for very few PrPC 
ligands, including the stress-inducible protein I (STI1), the 37-kDa/67-kDa laminin receptor 
precursor (LRP), and the neuronal cell adhesion molecule (NCAM). 
STI1 is a heat shock protein first described in a macromolecular complex with Hsp70 and 
Hsp90 chaperone family proteins, mainly localized in the cytoplasm but a small fraction of the 
total protein is present at the cell membrane, where it seems to interact with PrPC [141]. The 
interaction between STI1 and PrPC induces neuroprotective signals that rescue cells from 
apoptosis via cAMP/protein kinase A and the Erk signaling pathways [142]. 
LRP is another cell surface PrPC ligand. It mediates internalization of PrPC and directs the 
complex through clathrin coated pits. LRP was suggested to act as a putative PrPC receptor 
because it was shown to co-localize with PrPC on the surface of both N2a and baby hamster 
kidney cells. 
NCAM belongs to immunoglobulin (Ig) superfamily cell adhesion molecules (CAMs) and it is 
present on the cell surface of neurons, astrocytes and oligodendrocytes, where it mediates 
homophilic and heterophilic cell adhesion [143]. NCAM is involved in neuronal migration, axon 
growth and guidance, as well as in synaptic plasticity associated with learning and memory 
[144]. Alternative splicing of the NCAM1 gene results in isoforms of three size classes, that 
differ in their membrane attachment and cytosolic regions (namely, NCAM120, NCAM140 and 
NCAM180), but share an extracellular domain consisting of five Igs and two fibronectin type-3 
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(FNIII1,2) domains (Figure 1.9 A). Variable use of alternative exons in the extracellular domain 
results in small insertions into Ig4 or between the FNIII1,2 domains. 
 
 
 
Figure 1.9. (A) Schematic drawing of three NCAM isoforms. (B) Schematic representations of the zipper 
adhesion complexes formed by NCAM. The compact zippers are stabilized by Ig1-to-Ig3 and Ig2-to- Ig2 
interactions between Ig1-2-3 cis dimers originating from two opposing cell membranes. (C) The flat zipper is 
stabilized by Ig2-to-Ig3 interactions between Ig1-2-3 cis dimers originating from two opposing cell membranes. (D) 
The two types of zippers may coexist as observed in the crystal and will result in formation of a double zipper-like 
adhesion complex (modified from [145]). 
 
 
NCAM function is further regulated by an unusual posttranslational modification consisting  
in the addition of polysialic acid to Ig5 [146, 147]. 
NCAM physiological function is mediated by multiple modes of homophilic interaction 
through NCAM Ig domains [145]. The Ig1 and Ig2 domains mediate dimerization of NCAM 
molecules situated on the same cell surface (cis interactions), whereas the Ig3 domain mediates 
interactions between NCAM molecules expressed on the surface of opposing cells 
(trans interactions) through simultaneous binding to the Ig1 and Ig2 modules. This arrangement 
results in two perpendicular zippers forming a double zipper-like NCAM adhesion complex 
(Figure 1.9 B-D). 
Additionally, NCAM is also engaged in heterophilic interactions, i.e. NCAM can bind other 
protein partners modulating different functions. Different groups have deeply investigated the 
structural and molecular basis governing the interaction between the NCAM FNIII1,2 domain 
and the fibroblast growth factor receptor 1 (FGFR1) [148, 149]. 
A B
C
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Besides the interaction with FGFR1, NCAM can bind PrPC and engages different cellular 
responses. This part will be discussed in more detailed in the following section. 
 
1.7.2.1. Biological relevance of PrPC-NCAM interaction  
PrPC has been first identified in a complex with NCAM by chemical cross-linking [150]. Both 
PrPC and NCAM have been implicated in signaling cascades involving the p59fyn non-receptor 
tyrosine kinase (fyn) [151] and fyn is involved in NCAM-induced neurite outgrowth [152]. PrPC 
and NCAM in cultured hippocampal neurons were found to co-localization along neurites and in 
growth cones [153]. 
PrPC accumulates in lipid rafts enriched in fyn (Figure 1.10 A). NCAM binds to RPTPα 
outside of lipid rafts, activating fyn, and therefore it is excluded from lipid rafts. Clustering of 
NCAM results in its palmitoylation that redistributes NCAM to lipid rafts [154]. In lipid rafts, 
cis interactions between NCAM and PrPC further recruit and stabilize NCAM in lipid 
microdomains activating fyn via NCAM, and finally resulting in neurite outgrowth. 
In NCAM-deficient and PrPC-deficient neurons, NCAM/PrPC-dependent neurite outgrowth is 
arrested, indicating that PrPC is involved in nervous system development cooperating with 
NCAM as a signaling receptor (Figure 1.10 B-C). 
Enzyme-linked immunosorbent assay (ELISA) experiments using an NCAM-derived peptides 
library against the recombinant full-length MoPrP have shown that FNIII1,2 domain shares 
highest affinity for MoPrP [155]. N2a cells expressing a MoPrP deletion mutant, including 
residues from 144 to 173, did not form cross-linking with NCAM, suggesting that the interaction 
between PrPC and NCAM occurs through this amino acidic region.  
 
 
 
Figure 1.10. Signals cascade following the interaction between NCAM and PrPC (modified from [153]). 
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1.7.3. PrPC functions suggested by metal interaction 
Many efforts have been made to understand the role of metal ions in both PrPC physiology as 
well as in prion pathogenesis. To date, evidences support the idea that the physiological function 
of PrPC is related to its metal-binding properties. PrPC binds copper in vivo, and cultured cells 
and neurons chronically exposed to high Cu2+ concentrations show increased expression of 
Prnp. Moreover, it has been shown that copper stimulates rapid endocytosis and trafficking of 
PrPC, through binding to the octapeptide region (OR) region [17]. 
PrPC takes up the Cu2+ through its flexible N-terminal domain, composed of five copper 
binding sites in this domain: four in the OR and one in non-octapeptide region (non-OR region) 
or fifth copper binding site [156]. 
The OR is an evolutionarily conserved motif, although the number of the repeated units can 
vary among species (Figure 1.11 A). In HuPrP the OR consists of one nonapeptide, 
PQGGGGWGQ and four repeats of the sequence PHGGGWGQ. Within the OR, histidine and 
tryptophan residues were found to be essential for the binding of copper and other divalent 
cations such as zinc, nichel, iron and manganese [157], but the highest affinity is for Cu2+ 
(around 5-8 µM) [74]. In a single octapeptide the binding is mediated by the histidine and 
tryptophan which form a β-turn conformation wrapped around and coordinating Cu2+ (Figure 
1.11 B) [158]. The OR does not appear to be essential for prion infectivity [159].  However, the 
insertion of extra octapeptide repeats is related to inherited forms of prion diseases [160, 161] 
suggesting that the OR may play a role in modulating the conversion of the protein into the 
pathogenic form. The binding of Cu2+ suggests that PrPC may be involved in copper 
homeostasis. 
 
 
 
 
Figure 1.11. Schematic representation of PrPC and its Cu(II) binding sites. (A) A sequence alignment for the 
Cu binding regions is shown including sequences from different mammalian prion proteins (PrP): HuPrP (human, 
Homo sapiens, NCBI accession code AAA60182), MoPrP (mouse, Mus musculus, AAA39997), SHaPrP (Syrian 
hamster, Mesocricetus auratus, AAA37091) and OvPrP (sheep, Ovis aries, AFM91142.1) (modified from [162]. (B)  
X-ray crystal structure of the Cu2+-HGGGW complex (modified from [163]). 
 
 
Additional histidines at position 96 and 111 are involved in high affinity copper binding and 
form the non-OR, or fifth, copper binding site [164, 165]. This region seems critical for prion 
conversion. However, animals treated with excess of copper [166] or with metal chelators [167] 
in both cases displayed a delayed onset of disease symptoms. These data indicate that there is no 
consensus and, often, contrasting results regarding the specific physiological function of copper 
binding, as well as the implication of this metal in developing prion diseases. 
B
(PHGGGWGQ) 4 GGGTHSQWNKPSKPKTN M KHMAGAAAAGAVVGGLG
(PHGGGWGQ) 4 GGGTHNQWNKPNKPKTS MKHMAGAAAAGAVVGGLG
(PHGGGWGQ) 4 GG—SHSQWNKPSKPKTN MKH V AGAAAAGAVVGGLG
Human
Mouse
Hamster
Sheep
OR non-OR palindromic motif
61 93 103 113 123
A
(PHGGGWGQ) 4 GGGTHNQWNKPSKPKTN L KH V A GAAAAGAVVGGLG
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1.7.3.1. The binding of copper at the octapeptide repeats binding sites.  
The OR region in human prion protein is composed of highly conserved multiple tandem 
repeats of the same eight amino acids (PHGGGWGQ). This region can bind four copper ions 
with identical coordination geometry [168, 169]. Each repeat contains a histidine which is 
generally accepted to be the primary residue responsible for the copper coordination [158, 170]. 
At pH 7.4, the copper coordination to the octapeptide repeat region is dependent on the relative 
amount of available copper and on the pH of the surrounding environment [163, 170] (Figure 
1.12). 
 
 
 
Figure 1.12. Models of the three coordination modes of copper binding to the octarepeat region. (A) 
Component 1, (B) component 2 and (C) component 3 (modified from [171]). 
 
 
At low copper occupancy, a single Cu2+ ion is bound by the imidazole side chains of four OR 
histidine residues in a square planar geometry. This multi-His coordination mode is commonly 
referred to as component 3 (Figure 1.12 C), with a dissociation constants ranging from ∼0.1 to 
10 nM [172, 173]. As the copper-to-protein ratio is increased, OR binding transitions through an 
intermediate two-His binding mode (component 2) (Figure 1.12 B) to a high-occupancy 
structure in which each individual repeat of PHGGGWGQ coordinates a single Cu2+ ion. This 
high-occupancy binding mode, known as component 1 (Figure 1.12 A), coordinates copper 
through the imidazole nitrogen of histidine, the backbone amide nitrogens from the first and 
second glycines immediately following the histidine, and the carbonyl oxygen of the second 
glycine [158, 174]. 
 
1.7.3.2. The binding of copper at non-octapeptide repeat binding site  
Several studies have shown that copper is able to bind outside of the octarepeat region of PrPC 
[158, 161, 165]. Jones and co-authors discovered a multi-co-ordination mode that was strongly 
influenced by pH. They found three coordinations, all of them display a square planar geometry 
(Figure 1.13). At pH 7.5 and above, a 4N complex dominates, while at pH 6.0, a ligand 
rearrangement shifts the coordination to a 3N1O configuration. At low pH, a multi histidine 
residue 2N2O coordination dominates [171]. 
 
 
A B C
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Figure 1.13. Models of the Cu2+ coordination modes in the non-octapeptide repeat site. (A) Component 1 is a 
4N complex that dominate at pH 7.5 and above, (B) Component 2 is a 3N1O complex that exists at pH 6, (C) 
Component 3 is a 2N2O complex that may exist at pH 5.5 (modified from [171]). 
 
 
1.8 The role of the N-terminal domain in the PrPC function and conversion 
 
As anticipated, PrPC consists in two distinct structural moieties: a flexible and disordered N-
terminal tail and the globular C-terminal domain. Several studies suggest that the N-terminal 
domain may act as a molecular sensor that allow PrPC to relay intracellular neuroprotective 
signals, but can also modulate prion conversion, being a target of the most effective antiprion 
compounds. 
Both the N- and C-terminal domains may also be physically divided following a proteolytic 
processing of PrPC in a region termed “a-cleavage” releasing PrPN1 and PrPC1 [175]. A minor 
cleavage termed “b-cleavage” also occurs at residues 90–91, releasing peptides PrPN2 and 
PrPC2 [176]. Interestingly, this cleavage is up-regulated in TSE [175]. Another type of cleavage 
within the OR is induced by reactive oxygen species in the presence of Cu2+ [177]. The cleavage 
of PrPC may regulate the function of the protein in at least two ways; inactivation of existing 
functions as well as unmasking new activities. 
Several evidences pointed out that N- and C-terminal domain may be physiologically 
connected. It was proposed that the C-terminal domain act as a molecular regulator of the N-
terminal domain. Indeed, mAb binding at specific epitopes in the globular domain disrupts the 
normal regulation, leading the N-terminal domain to carry out toxic effects. Deletion of N-
terminal segments rescue the normal functions. It has been proposed that this coupling is due to 
a direct interaction between the C- and N-terminal domain. In support to this hypothesis, 
EXAFS studies on the human pathological point mutation, Q212P -which is located in the 
globular domain- shown that the mutation alters the coordination geometry of the non-OR 
region in the N-terminal, supporting the involvement of both C- and N-terminal domain [164]. 
Recently, NMR and electron paramagnetic resonance (EPR) spectroscopy studies revealed that 
interaction between C- and N-terminal domain is mediated by copper ions. In this study there 
were identified the residues in the globular domain involved in the interaction, but not residues 
of the N-terminal domain because of the high flexibility [178]. 
Other studies highlighted that in contrast to most GPI-anchored proteins, the PrPC’s GPI 
anchor does not seem to have a predominant control on PrPC internalization. Several studies 
have shown that N-terminal domain is necessary and sufficient for constitutive endocytosis of 
PrPC via clathrin-coated pits in primary neurons and a variety of cell lines [17, 179, 180]. 
A B
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The N-terminal domain is also essential for the movement of PrPC outside of lipid rafts before 
its internalization. In the absence of a transmembrane domain, PrPC cannot directly interact with 
cytoplasmic clathrin-associated adaptor protein complexes.  
 
1.8.1. The neuroprotective role of the PrPC hydrophobic domain 
Several mouse models have demonstrated the neuroprotective role of PrPC hydrophobic 
domain (HD). Ataxia and degeneration of cerebellar granule neurons occurred in transgenic 
mice expressing a PrP construct deleted of residues 32–121 or 32–134 [181]. Mice expressing a 
PrP construct with shorter deletions (i.e. D32-80, D32–93, D32–106, or D23–88) did not display 
neurological symptoms [182]. These results showed a correlation between the absence of the 
HD (amino acids 112–133) and toxicity of the transgene. 
Transgenic models also showed that the HD is required for myelin maintenance. Selective 
depletion of PrPC from neurons but not from Schwann cells results in chronic peripheral 
demyelinating polyneuropathy in mice [183].  
Prnp-/- mice displayed three times larger infarct size compared with Prnp+/+ mice [184]. Mice 
expressing a PrPC mutant deleted of amino acids 32–93 had infarct size similar to Prnp-/- mice, 
indicating a neuroprotective function for this domain in vivo. 
A transgenic mouse model indicated that PrPC neuroprotective domain maps to amino acids 
23–88 [182, 185]. In addition, fusion of N-terminus of PrPC (amino acids 1–133) to Doppel 
completely reversed Doppel toxicity in a transgenic mouse [185]. The anti-Doppel activity of 
PrPC N-terminal domain 23–90 was also confirmed in SH-SY5Y cells [186]. 
Amyloid precursor protein (APP) cleavage initiates the production of Ab and is considered as 
one of the key molecular events in Alzheimer’s disease. Removal and over-expression of PrPC 
in SH-SY5Y cells increased and decreased b-secretase cleavage of APP respectively [187]. In a 
model proposed by the authors, GAGs connect PrPC to b-secretase and prevent the protease 
from accessing APP [187, 188]. In vivo, APP and Ab levels do not depend on the presence of 
PrPC and a role for PrPC in APP metabolism seems therefore unlikely [189]. 
 
1.8.2. The neurotoxic role of the N-terminal domain of PrPC 
The interaction between Ab oligomers and PrPC suggested that PrPC may act as a receptor and 
mediates oligomer-induced synaptic toxicity. Indeed, addition of synthetic Ab42 oligomers to 
hippocampal slices from Prnp+/+ but not Prnp-/- mice reduced LTP [190]. Subsequently, it has 
been shown that absence of PrPC in a transgenic Alzheimer mouse rescues deficits in spatial 
learning and memory, confirming the role of PrPC as a mediator of Ab toxicity [189]. Ab42 
oligomers inhibited the constitutive endocytosis of PrPC in cultured cell lines and hippocampal 
neurons, resulting in a large increase of PrPC at the cell surface within minutes after addition of 
oligomers [191]. This inhibition likely results from the binding of Ab42 oligomers to the N-
terminal domain and interference with the endocytic signal peptide. Thus, the N-terminal 
domain of PrPC may act as a general receptor for toxic b-sheet conformers [192]. 
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1.8.3. The role of the N-terminal domain of PrPC in prion conversion 
Although the region comprising the OR region is not essential for prion replication, its deletion 
results in extended incubation times and altered manifestations in the pathology in animals 
experimentally inoculated with mouse adapted scrapie prions [181].  
Two mouse models with point mutations within the N-terminal domain confirmed the 
importance of this region for prion conversion. First, a two amino-acid substitution at amino 
acids 108 (leucine to methionine) and 111 (valine to methionine) were associated with a 
prolonged incubation time in mice challenged with four different strains of murine prions [193]. 
Second, a single amino-acid substitution from proline to leucine at position 101 considerably 
altered prion incubation time and targeting of the brain pathology after challenge with prions 
from murine, hamster, sheep and human sources [193, 194]. Experiments performed with 
recombinant PrP constructs and in persistently infected cultured cells strengthened the 
significance of the N-terminal domain of PrPC in prion conversion. Deletions of amino acids 34–
94 and 34–113 inhibited the formation and altered the conformation of hamster PrPSc in a cell-
free conversion assay [195]. Deletion of amino acids 95–107 and 112–119 also prevented the 
formation of PrPSc in ScN2a cells [32, 196]. 
In cell-free conversion assays, conversion of PrPC into PrPSc is stimulated by heparan 
sulphates and heparin sulphate proteoglycans [197, 198]. In particular GAGs might act as a 
polyanionic scaffold facilitating the interaction between PrPC and PrPSc [199]. Interestingly, the 
N-terminal domain of pathological mutants of PrP have a more exposed N-terminus and display 
enhanced heparin binding [28]. Mutants also formed aggregates more readily than wild-type 
PrPC, suggesting that GAGs participate in prion conversion. 
The N-terminal domain is also a site for several ligands with antiprion activites. One important 
class are heparan sulphate proteoglycans. Heparan sulphate mediates direct interactions of 
proteoglycans with proteins, including PrPC N-terminus, promoting the association of PrP with 
lipid rafts and enhancing the conversion in prion infected N2a cells [200]. Moreover, sulphated 
GAGs enhance internalization of PrPC in cultured cells, which may explain their inhibitory 
effects on prion conversion in cultured cells [179, 200]. 
Degenerate phosphorothioate oligodeoxynucleotides are also considered inhibitors of PrPSc in 
prion-infected N2a [199]. Several studies suggest a common mechanism of action of the most 
effective antiprion compounds in the N-terminal domain. Anionic antiprion molecules may 
interact with cationic amino acids and planar aromatic molecules could interact with the 
repeated tryptophan residues and bridge several PrPC molecules. After clustering and/or 
internalization, PrPC becomes unable to convert into PrPSc. 
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1.9 Aims of the research 
 
The conversion of the cellular prion protein PrPC into the infectious isoform (PrPSc) is the key 
event in prion diseases. The physiological role of PrPC, as well as the structural and molecular 
mechanisms leading to PrPSc conversion, remains largely unknown. Putative roles for PrPC are 
based on its localization in the central and peripheral nervous systems and on PrPC-interacting 
molecules or metal ions. 
 
In the present thesis, the interactions of the cellular prion protein with NCAM and copper ions 
have been investigated in the context of their functional role. In particular, objects of this thesis 
are: 
 
 
i. Identification of the structural determinant responsible for the interaction between PrPC and 
NCAM.  
Despite the inherent structural disorder of the PrPC N-terminal domain, which can mediate 
interaction with both metals and cellular polyanions (e.g. sulfate proteoglycans), the binding 
with physiological protein partners has not been proved yet.  
Cell biology, biophysical and structural investigations on the interaction between NCAM 
and HuPrP were performed, providing the first structural evidence of the interaction between 
PrP and NCAM. 
 
 
ii. Understanding the role of copper in prion conversion and susceptibility with a special focus 
on the fifth copper binding site. 
The molecular mechanisms of prion conversion are still debated [201]. NMR-based studies 
on HuPrP and mouse PrP (MoPrP) globular domains have identified the β2-α2 loop as 
important element able to modulate the susceptibility of a given species to prion disease [25, 
108-112]. However, recent studies have highlighted also the importance of the N-terminal 
region in promoting structural rearrangements to PrPSc. The segment from residues 90 to 127 
may act as an alternate N-terminal switch for prion conversion because of the ability of a 
palindromic motif AGAAAAGA (residues 113-120) to initiate β-sheet enrichment [40] and 
to form neurotoxic species [196, 202, 203]. The proximity of the non-OR copper binding site 
to this palindromic motif suggests a pathological link between copper binding to this site and 
prion conversion. 
  
 
 
CHAPTER II 
 
 
 
MATERIAL AND METHODS 
 
 
2.1 STED nanoscopy experiments 
 
Note: STED microscopy was performed at the NanoBiophotonics Department (Max Plank 
Institute for Biophysical Chemistry, Göttingen, Germany) and analyzed by Dr. Ladan Amin 
(SISSA). For this reason, we have moved the related Materials and Methods in the Appendix II, 
Section I. 
 
2.2 Molecular biology experiments 
 
2.2.1 Cloning of MoPrP and HuPrP in pET-11a vector 
The pET-11a vector expressing the MoPrP(23-230) were kindly provided by the group of Prof. 
Jesús Requena (Universidade de Santiago de Compostela, Spain). 
The WT MoPrP(89-230) was amplified from genomic murine DNA by PCR using primers 5’ 
–GGA ATT CCA TAT GGG CCA AGG AGG GGG TAC CCA T- 3’ and 5’ –TCA GCT GGA 
TCT TCT CCC GTC GTA ATA GGC CGG ATC CCG- 3’. 
The WT HuPrP(23-231, M129) was amplified from pGEM-T Easy vector::HuPrP complete 
ORF by PCR using primers 5’ – GGA ATT CCA TAT GAA GAA GCG CCC GAA GCC TGG 
A- 3’ and 5’ –CGG GAT CCC TAG CTC GAT CCT CTC TGG TAA TAG GCC TGA- 3’. 
The WT HuPrP(90-231, M129) was amplified from genomic human DNA by PCR using 
primers 5’-GGA ATT CCA TAT GGG TCA AGG AGG TGG CAC CCA C-3’ and 5’-CGG 
GAT CCC TAG CTC GAT CCT CTC TGG TAA TAG GCC TGA-3’. 
The WT HuPrP(23-144, M129) was amplified from pET-11a::HuPrP (23-231, WT) by PCR 
using primers 5’ –TTT CGG CAG TGA CTA AGA GGA CCG TTA CTA T- 3’ and 5’ –ATA 
GTA ACG GTC CTC TTA GTC ACT GCC GAA A- 3’. 
The DNA product was then inserted into pET-11a vector (Novagen) using NdeI and BamHI 
restriction sites. The PCR were performed using the Vent (New England Biolab) DNA 
polymerase according to manufacturer’s instructions. Plasmid DNA was purified using the 
QIAprep Spin Miniprep Kit (Quiagen). The cloned DNA sequences were verified by 
sequencing. 
Peptides HuPrP (23-89), HuPrP (23-50), HuPrP (60-68), HuPrP (93-114), HuPrP (93-114, 
P102L) used for NMR experiments were purchased from Chematek Spa.  
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2.2.2 Cloning of FNIII1,2, FNIII1 and FNIII2 in pET-11a vector 
The FNIII1,2, FNIII1 and FNIII2 domains were PCR amplified from pCEP-Pu vector 
encoding for FNIII1,2 (kindly provided by Dr. Federico Carafoli, Imperial College London, 
London, UK) and inserted into a modified pET11a vector (i.e. carrying a C-terminal uncleavable 
HisTag) using restriction free cloning protocol. Our FNIII1,2 and FNIII1 numbering schemes 
correspond to Carafoli et al. 2008 [204]. 
 
2.2.3 Cloning of OpPrP, BvPrP and OvPrP in pET-11a vector 
The pET-11a vector expressing the OpPrP (100-237), BvPrP (91-231), OvPrP (93-233, VRQ) 
and OvPrP (93-233, ARR) were purchased from Chematek Spa. 
 
2.2.4 Mutagenesis of HuPrP and MoPrP constructs 
The WT HuPrP(90-231, M129) was amplified from genomic human DNA by PCR using 
primers 5’-GGA ATT CCA TAT GGG TCA AGG AGG TGG CAC CCA C-3’ and 5’-CGG 
GAT CCC TAG CTC GAT CCT CTC TGG TAA TAG GCC TGA-3’. The DNA product was 
then inserted into pET-11a vector (Novagen) using NdeI and BamHI restriction sites. 
The PCR were performed using the Vent (New England Biolab) DNA polymerase according 
to manufacturer’s instructions. Plasmid DNA was purified using the QIAprep Spin Miniprep Kit 
(Quiagen). The cloned DNA sequences were verified by sequencing. 
The HuPrP and MoPrP variants were constructed using the QuikChangeTM kit (Stratagene) 
according to manufacturer’s instructions. Q212P and P102L mutations were inserted on 
HuPrP(90-231) construct. H60Y, H68Y, H76Y and H84Y were inserted into pcDNA::MoPrP(1-
254)WT, pcDNA::MoPrP(1-254)WT3F4 or pET::MoPrP(23-230). We used the following 
primers for the mutagenesis: 
Q212P mutation: 5’-CGC GTG GTT GAG CCG ATG TGT ATC ACC C- 3’ and 5’-GGG 
TGA TAC ACA TCG GCT CAA CCA CGC G- 3’. 
P102L mutation: 5’-ACA GTC AGT GGA ACA AGC TGA GTA AGC CAA AAA CCA A- 
3’ and 5’-TTG GTT TTT GGC TTA CTC AGC TTG TTC CAC TGA CTG T- 3’. 
H96Y mutation: 5’-CAA GGA GGG GGT ACC TAT AAT CAG TGG AAC AAG C-3’ and 
5’ –GCT TGT TCC ACT GAT TAT AGG TAC CCC CTC CTT G- 3’. 
H60Y mutation: 5’ –CAG CCC TAC GGT GGT GGC TGG GGA CAA- 3’ and 5’ -TTG TCC 
CCA GCC ACC ACC GTA GGG CTG- 3’. 
H68Y mutation: 5’ –GGG GAC AAC CCT ATG GGG GCA GCT GG- 3’ and 5’ – CCA GCT 
GCC CCC ATA GGG TTG TCC CC- 3’. 
H76Y mutation: 5’ –AGC TGG GGA CAA CCT TAT GGT GGT AGT TGG G- 3’ and 5’ –
CCC AAC TAC CAC CAT AAG GTT GTC CCC AGC T- 3’ 
H84Y mutation: 5’ –TGG GGT CAG CCC TAT GGC GGT GGA TGG- 3’ and 5’ –CCA 
TCC ACC GCC ATA GGG CTG ACC CCA- 3’.  
All the constructs were verified by sequencing. 
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2.3 Protein expression and inclusion bodies isolation 
 
2.3.1 Prion proteins expression in LB medium. 
For recombinant proteins expression we always used Escherichia coli BL21(DE3) strain 
(Stratagene). For all recombinant MoPrP and HuPrP variants and OpPrP, BvPrP and OvPrP 
constructs we always used Escherichia coli BL21(DE3) strain (Stratagene) and produced in LB 
medium (10 g trypton, 5 g yeast extract, 10 g NaCl) according to the following protocol: freshly 
transformed 100 mL overnight culture of E. coli BL21 (DE3) cells was added to 2 L of LB 
medium plus ampicillin (100 µg/mL) in a Biostat B plus 2 L bioreactor (Sartorius) which allows 
for an automated control of pH, temperature and pO2. The expression was induced at 0.8 OD600 
with 1 mM IPTG. The cells were harvested 16 hours after induction by centrifugation at 4000 g, 
4 °C for 30 min.  
 
2.3.2 FNIII1,2, FNIII1 and FNIII2 expression for NMR structural studies. 
For double labeled recombinant proteins expression, the cultures were grown in M9 minimal 
medium (MM) using the recipe described by [205]. We have expressed our proteins using the 2 
L bioreactor (Sartorius Biostat-B plus), as for the PrPs.  
Small scale expression trials, aimed at increasing the FNIII expression level in M9 MM, 
included the following conditions: different concentrations of the inducer isopropyl b-D-
galactopyranoside (0.4, 0.6, 0.8 and 1 mM IPTG) and two temperature conditions (30 and 
37°C). For isotope labeling, 4 g/L [13C6] glucose and 1 g/L [15N] ammonium chloride were 
added. 
The final protocol for the large scale expression of double labeled 13C,15N FNIII1,2, FNIII1 
and FNIII2 was the following: freshly transformed 100 mL overnight culture of E. coli BL21 
(DE3) cells was pelleted by centrifugation at 4000 g, 4°C for 30 min. Bacterial pellet was 
resuspended with 50 mL double labeled M9 MM and added at 37°C to 2 L of M9 MM plus 
ampicillin (100 µg/mL). At 0.8 OD600 expression was induced with IPTG to a final 
concentration of 0.25 mM. The cells were harvested 12 hours after induction and the bacteria 
were pelleted by centrifugation at 4000 g, 4°C for 30 min. 
 
2.3.3 Isolation of inclusion bodies 
The overexpression of all our proteins in E. coli BL21 (DE3) resulted in the formation of 
insoluble bacterial inclusion bodies. We developed a common inclusion bodies extraction 
protocol. Bacterial paste was resuspended in 25 mM Tris-HCl, 5 mM EDTA, 0.8% TritonX-100, 
1 mM PMSF, pH 8 and lysed at RT by French press (EmulsiFlex-C3). Three cycles of 
mechanical lysis at 100 MPa were sufficient to disrupt the cells. Inclusion bodies were separated 
by centrifugation (30 min, 10,000 g at 4°C), rinsed in 25 mM Tris-HCl, 5 mM EDTA, 0.8% 
TritonX100, pH 8, and then in bi-distilled water several times. Pure inclusion bodies were 
solubilized 12 hrs at 37°C in 5 volumes of 8M GndHCl, and then centrifuged 30 min, 10000 g at 
4°C to remove bacterial debris.  
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2.4 Protein purification 
 
2.4.1 HuPrP, MoPrP variants and other mammalian PrPs purification 
The dissolved IBs in 8 M GndHCl were diluted to 6 M GndHCl using 50 mM Tris, 1 M NaCl, 
pH 8.0 then loaded onto a 5 mL HisTrap crude column (GE Healthcare) in binding buffer (2 M 
GndHCl, 500 mM NaCl, 20 mM Tris, 20 mM imidazole, pH 8.0). After that, the column was 
washed with 3 column volume (CV) of binding buffer and eluted with a gradient from 0-100 % 
of elution buffer (5 M GndHCl, 500 mM NaCl, 20 mM Tris, 500 mM imidazole, pH 8.0) at 5 
mL/min in 20 min. Finally, the PrP-contained fractions were loaded onto gel filtration column 
(Superdex 200 26/60, GE) and eluted with 6 M GndHCl, 25 mM Tris-HCl, 5 mM EDTA, pH 8 
at a flow rate of 2 mL/min. Purified protein was analyzed by SDS-PAGE. Protein concentration 
was determined by UV at 280 nm and stored at −80 °C before use.  
 
2.4.2 FNIII1,2, FNIII1 and FNIII2 purification for NMR structural studies 
Double labeled 13C, 15N FNIII1,2, FNIII1 and FNIII2 were purified according to the following 
protocol. The 8M GndHCl inclusion bodies solutions were diluted to 6M GndHCl using buffer 
80 mM Tris, 2 M NaCl, pH 8. The solution was loaded 1 mL/min onto a 5 mL HisTrap column 
(GE Healthcare) equilibrated in binding buffer (2 M GndHCl, 500 mM NaCl, 20 mM Tris, 20 
mM imidazole, pH 8) and eluted 5 mL/min using a gradient of elution buffer (2 M GndHCl, 500 
mM NaCl, 20 mM Tris, 500 mM imidazole, pH 8). Purified proteins were analyzed by SDS-
polyacrylamide gel electrophoresis under reducing condition. 
 
 
2.5 Protein refolding 
 
Lyophilized prion proteins were solubilized in sterile ddH2O to a final concentration of 5 
mg/mL. To 1 mL of 5 mg/mL of protein we added 4 mL of 8 M GndHCl, and then we leaved 
the samples at RT for 30 min or stored at -80°C before use. For refolding, the GndHCl solutions 
were rapidly diluted to a protein concentration of 0.1 mg/mL using buffer 25 mM Tris, 5 mM 
EDTA, pH 8. The samples were then dialyzed against refolding buffer (20 mM NaOAc, 0.005% 
NaN3, pH 5.5) using a Spectra/Por membrane (cutoff of 3 kDa), until a final GndHCl 
concentration of about 10 µM. 
 
2.5.1 Protein quantification 
The protein concentration was determined, according to the Lambert-Beer law, by measuring the 
absorption at 280 nm (A280). 
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2.6 Surface plasmon resonance experiments 
 
Binding kinetics were determined on biacore 2000 (GE Healthcare). Ten µg of NCAM was 
diluted in 10 mM NaOAC, pH 5.2 and immobilized on CM5 chip activated with N-
hydroxysuccinimide (NHS), N-ethyl-N-(3-dimethylaminopropyl) carbodiimide (EDC), using a 
flow rate of 5 µL/min. A steady signal of about 400 response units (RU) was obtained after 
immobilization and blocking with ethanol amine. All kinetic SPR analysis were run at 30 
µL/min flow rate in PBS, 0.05% Tween20 and 3 mM ethylenediaminetetraacetic acid (EDTA) at 
25 °C. After each cycle, the surface was regeneration with 60 s pulse of 100 mM glycine, pH 
1.5. Association rates (Kon) and dissociation rates (Koff) were obtained using a 1:1 Langmiur 
binding model (Biacore evaluation software version 4.1). The equilibrium dissociation constant 
(Kd) was calculated from the ratio Koff/Kon. 
 
 
2.7 ELISA experiments 
 
BCL was immobilized at 0.5 µM and titrated with full-length HuPrP (0-5 µM). Antigen was 
detected using anti-PrPC SAF34 antibody which recognizes an epitope corresponding to the 
octapeptide repeats region (residues 60-91) [206]. 
 
 
2.8 NMR spectroscopy experiments 
 
Note: all the NMR experiments here presented were performed in collaboration with the group 
of Prof. Janez Plavec at the Slovenian NMR Centre, National Institute of Chemistry, Ljubljana, 
Slovenia. 
 
2.8.1 Sample preparation 
Refolded proteins were concentrated to 0.8-1 mM using Amicon centrifugal cells (Millipore). 
The same device was used for buffer exchange. 
 
2.8.2 NMR spectroscopy 
All NMR experiments used for structure determination were performed on 13C, 15N 
isotopically labelled FNIII2 domain on the Varian VNMRS 800 MHz NMR spectrometer 
equipped with triple 1H/13C/15N resonance cryogenic probe head with inverse detection at 298 K. 
NMR sample contained 0.9 mM FNIII2 domain in 50 mM TBS buffer pH 7.45 and 150 mM 
NaCl. NMR experiments for HN and HC detection were performed in 90%/10% H2O/D2O and 
100% deuterated buffer, respectively. Sequence-specific assignment of the backbone resonances 
for FNIII2 domain was obtained using standard double resonance 15N-HSQC and triple 
resonance NMR experiments HNCO, HN(CO)CA, HNCA, HN(CO)CACB and HNCACB. 1H 
and 13C resonances of aliphatic and aromatic side chains were assigned using 13C-HSQC and 
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HAHB(CO)NH, CC(CO)NH, (H)CCH-TOCSY and 13C-edited HSQC-NOESY experiments. 
NOEs contacts were determined in 3D 15N- and 13C-edited HSQC-NOESY experiments in order 
to perform structure calculation.  
 
2.8.3 Structure calculations 
The structure modelling of FNIII2 domain was performed using program CYANA 3.0 [207]. 
Structure refinement using explicit solvent model was performed by YASARA program [208]. 
An ensemble of 20 lowest energies structures of FNIII2 domain was validated by web server 
software ICing [209]. 
 
2.8.4 Titrations with HuPrP peptides 
Titration of 13C, 15N isotopically labelled FNIII2 domain with unlabelled HuPrP(23-144) was 
performed in 25 mM HEPES buffer, pH 7.0. Titrations of labelled FNIII2 domain were also 
done with unlabelled HuPrP(23-50), HuPrP(23-89), HuPrP(60-68), HuPrP(93-114), HuPrP(93-
114, P102L) peptides at pH 6.0 (20 mM NaOAc buffer, 0.35 mM labelled FNIII2 domain per 
titration experiments). Titrations were followed by analysis of Δδ(H,N) of FNIII2 domain in 
15N-HSQC experiments. All recorded spectra were processed by NMRPipe [210] software and 
analysed with CARA [211] and Sparky [212] software.  
Amide chemical shift changes were calculated for each non-overlapped cross-peak in 15N-
HSQC spectrum of FNIII2 domain according to Eq. (1) and (2): 
 𝛥𝛿 𝐻,𝑁 = (∆𝛿))+ + (0.154×𝛥𝛿3)+     … Eq. 1 𝛥𝛿),3 = 𝛿),3	56789 − 𝛿),3	;<==     … Eq. 2 
 
where ΔδH and ΔδN are defined as the difference in the 1H and 15N amide chemical shifts 
between the protein-peptide complex and the free state of FNIII2 domain [213]. 
 
2.8.5 Modelling the complex between FNIII2 domain and HuPrP(93-114, P102L) 
Modelling of complex between FNIII2 domain and HuPrP(93-114, P102L) was made with 
HADDOCK software [214, 215]. 
 
2.8.6 Accession number 
The chemical shift data were deposited in Biological Magnetic Resonance Data Bank 
(BMRDB). The atomic coordinates and structure factors (code 5LKN) have been deposited in 
the Protein Data Bank (PDB). 
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2.9 X-ray Absorption measurements 
 
Note: All X-ray absorption measurements were performed in collaboration with the group of 
Prof. Paola D’Angelo (Department of Chemistry, University of Rome “La Sapienza”, Rome, 
Italy).  
 
2.9.1 Sample preparation  
Refolded proteins were concentrated to 1.5-2 mM using Amicon centrifugal cells (Millipore). 
Samples with 1:1 Cu(II):WT and mutants HuPrP(90-231) ratio were prepared in 25 mM NaOAc 
pH 5.5 and 25 mM MOPS buffer pH 7.0. The Cu(I):WT and mutants HuPrP(90-231) complexes 
were generated reducing Cu(II) with 40 mM ascorbate.   
 
2.9.2 XAS spectra data collection 
X-ray absorption spectra were recorded at the European Synchrotron Radiation Facility 
(ESRF) on beam line BM30B, under ring conditions of 6.0 GeV and 180 mA. The spectra were 
collected at the Cu K-edge in fluorescence mode using a solid state 30-element Ge detector, with 
sample orientation at 45° to incident beam. The X-ray photon beam was vertically focused by a 
Ni−Pt mirror, and dynamically sagittally focused in the horizontal size. The monochromator was 
equipped with a Si(111) double crystal, in which the second crystal was elastically bent to a 
cylindrical cross section. The energy resolution at the Cu K-edge is 0.5 eV. The spectra were 
calibrated by assigning the first inflection point of the Cu foil spectrum to 8981 eV. All the 
spectra were collected at 10 K. For Cu(II) samples photo reduction is usually observed and thus 
the beam was moved to different spots of the sample at each scan. During collection, data were 
continuously monitored in order to insure sample homogeneity across the multiple spots 
collected from different sample-holder’s cells. For each sample, 12 spectra were recorded with a 
7 s/point collection statistic and averaged. The collection time was 25 min for each spectrum. 
 
2.9.3 EXAFS Data Analysis 
The analysis of the EXAFS data was carried out using the GNXAS code, which is based on a 
theoretical calculation of the X-ray absorption fine structure signal and a subsequent refinement 
of the structural parameters. In the GNXAS approach the interpretation of the experimental data 
is based on the decomposition of the EXAFS χ(k) signal into a summation over n-body 
distribution functions γ(n), calculated by means of the MS theory. Each signal has been 
calculated in the muffin-tin approximation using the Hedin-Lundqvist energy dependent 
exchange and correlation potential model, which includes inelastic loss effects. The analysis of 
the EXAFS spectra was carried out starting from the coordination models reported in the 
literature for the WT HuPrP and HuPrP Q212P proteins [164, 165, 216]. In particular the Cu(II) 
ion was found to have two different coordinations: in the former case the inner shell is formed 
by H96, H111, and two additional low Z ligands (oxygen or nitrogen donors), while M109 and 
Q98 are found in the Cu(II) axial positions. In the latter case the Cu(II) ion is coordinated by a 
single histidine ligand, namely H111, and three N/O scatterers, while one more distant sulphur 
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atom and a water molecule are found at longer distance. Based on these two models and 
considering the amino acidic residues present in the different mammalian PrPC, theoretical 
EXAFS spectra were calculated to include contributions from first shell two-body signals, and 
three-atom configurations. Previous investigations on model compounds have shown that a 
quantitative EXAFS analysis of systems containing histidine rings or having amino acidic 
residues that are chelated to the Cu(II) ion, requires a proper treatment of MS contributions 
[164, 165, 217]. The analysis of the OvPrP ARR and OpPrP resistant species has been carried 
out considering the coordination with a nitrogen atom of H111, with two oxygen atoms of S95 
that chelates the Cu(II) ion forming a ring in the equatorial pane (in this case two carbon atoms 
of the serine give rise to a single scattering contribution at about 2.86 Å), with an oxygen atom 
of Q98 and a sulphur atom of M109. The EXAFS spectra of the more susceptible OvPrP VRQ 
and BvPrP species have been analysed using the same model as HuPrP Q212P where the Cu(II) 
ion is coordinated by H111, Q98, M109 and a water molecule. The model χ(k) signal is then 
refined against the experimental data by using a least-squares minimization procedure in which 
structural and nonstructural parameters are allowed to float. The structural parameters are the 
bond distance (R) and bond variance (σ2R) for a two-body signal, the two shorter bond distances, 
the intervening angle (θ and φ), and the six covariance matrix elements for a three-body signal. 
In all cases two additional nonstructural parameters were minimized, namely E0 (core ionization 
threshold) and S02 (many body amplitude reduction factor). To establish error limits on the 
structural parameters, a number of selected parameters from the fit results were statistically 
analyzed using two-dimensional contour plots. This analysis examines correlations among 
fitting parameters and evaluates statistical errors in the determination of the copper coordination 
structure, as previously described [164]. Briefly, parameters with highest correlation dominate in 
the error estimate. The results of the EXAFS fits for all the systems are given in Table S1 and 
the best-fit curves are shown in Figure S1. The EXAFS spectra were analyzed in the k range 
between 2.4-12.6 Å-1. In all cases S02 was found equal to 0.9, while E0 was found 3 eV above the 
first inflection point of the spectra. 
 
 
2.10 Molecular Dynamics simulation on HuPrP WT 
 
Note: The simulation-based structural predictions were performed by Giordano Mancini 
(Scuola Normale Superiore, Pisa, Italy). For this reason, we have moved the related Materials 
and Methods in the Appendix II, Section II. 
 
 
2.11 Cell culture and transfection  
 
2.11.1 Neuroblastoma cell cultures 
N2a and ScN2a cells were cultured in Opti-MEM (GIBCO) media supplemented with 10% 
fetal bovine serum (FBS) and 1% penicillin-streptomycin, and incubated at 37 °C, 5% CO2. 
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Transient transfections were performed using X-treme gene DNA transfection kit (Roche 
Biochemicals) according to the manufacturer guidelines. Seventy-two hours post-transfection, 
the cells were collected for further analysis. 
 
2.11.2 Biochemical assays on PrPSc and PrPC 
Cell lysates were harvested in cold lysis buffer (10 mM TrisHCl pH 8.0, 150 mM NaCl, 0.5% 
Nonidet P-40 substitute, 0.5% sodium deoxycholate), quantified by BCA protein assay kit 
(Pierce) and stored at −20 °C until use. For protease-K (PK) digestion assay, quantified protein 
lysates were treated with PK (Roche) at 37 °C. ScN2a cell lysates were digested with 20 µg/mL 
of PK for 1 hour, while cell lysates from N2a cells transfected with either WT or H96Y 3F4-
MoPrP constructs were digested with 2 and 5 µg/mL of PK for 30 minutes. PK digestions were 
stopped by adding 2 mM phenylmethyl-sulphonyl fluoride. Subsequently, the samples were 
ultracentrifuged at 100,000 g for 1 h at 4 °C (Optima TL, Beckman Coulter, Inc.). The pellets 
were resuspended in sample buffer. The glycan modifications on PrPC were assessed using 
Endo-H and PNGase-F enzymes (New England Biolabs) according to the manufacturer 
instructions. Samples were loaded onto a 10% SDS-PAGE gel and immunoblotted on 
Immobilion PVDF (Millipore) membranes. Membranes were blocked with 5% (w/v) non-fat 
milk protein in TBS-T (0.05% Tween), incubated with 1:1000 anti-PrP antibody 3F4 (Covance), 
and developed by enhanced chemiluminescence (GE Healthcare). Band intensity was acquired 
using the UVI Soft software (UVITEC, Cambridge). Total PrPC expression levels in N2a and 
ScN2a cell lysates were normalized on β-actin value using 1:10,000 anti-β-actin Peroxidase 
(Sigma-Aldrich). The PrPSc PK-resistance levels in all the mutants were derived using as 
reference the PK-resistant band intensity of the ScN2a cells transfected with WT 3F4-MoPrP. 
To evaluate the role of copper in prion conversion, ScN2a cells were transiently transfected with 
pcDNA3.1::3F4-MoPrP(1–254) WT and pcDNA3.1::3F4-MoPrP(1–254) H96Y plasmids, 
treated for 48 hours with increasing concentration (10, 20, 30 and 40 µM) of cuprizone (CPZ, 
Sigma Aldrich) and immediately collected for lyses, PK digestion and immunoblot as described 
above. 
 
2.11.3 Fluorescence imaging 
Cells were grown on poly-L-lysine-coated coverslips for 24 hours before fixation in 4% 
paraformaldehyde and washed with PBS prior to blocking in 1% FBS, 0.3% Triton X-100. Cells 
were incubated at 4 °C for 12 hours in blocking buffer with anti-PrP primary antibodies, i.e. 3F4 
and D18 (InPro Biotechnology) monoclonal antibodies. The following day, cells were incubated 
for 1 hour with secondary antibodies conjugated with AlexaFluor. For PrPC cell surface 
detection, cells were incubated at 4 °C for 15 min and probed with 3F4 antibody. Cells were 
permeabilized with 0.2% Triton-X and stained with AlexaFlour-488 secondary antibody. To 
detect Thioflavin-S (ThS)-positive aggregates, transfected and non-transfected cells were fixed 
with 4% PFA/4% sucrose/1% Triton X-100 in PBS. For organelle markers, we used anti-
Calnexin (ER marker), anti-EEA1 (early endosome marker), anti-Tfn (recycling endosome 
marker), anti-M6PR (late endosomes marker) and anti-LAMP2 (lysosomes marker) purchased 
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from Abcam. Nuclei were stained with DAPI dye (VECTOR Laboratories). Images were 
acquired with a DMIR2 confocal microscope equipped with Leica Confocal Software (Leica). 
 
2.11.4 Monitoring the kinetics of in vitro fibril formation 
To monitor the formation of ThT-positive fibrils, we used 100 µg/mL of WT full-length 
MoPrP stored in acetate buffer (25 mM NaOAc, 6 M GdnHCl, pH 5.5) or Tris buffer (25 mM 
Tris-HCl, 6 M GdnHCl, pH 7.0). To induce protein polymerization in the amyloid seeding assay 
(ASA) we added a preformed PrPSc seed to the reaction purified from ScN2a transiently 
expressing either 3F4-tagged WT MoPrP or 3F4-tagged H96Y MoPrP according to our previous 
protocols. Data were analyzed and figures were produced using Origin 8.6 software. 
 
2.11.5 Prion formation in N2a cells 
N2a cells were transiently transfected with either 3F4-tagged WT or H96Y MoPrP and 
regularly passaged every 7 days up to passage (P) 8. Subsequently, the protein extracts were 
analyzed by PK digestion to monitor the presence of PK-resistant PrPSc levels through passages 
(see above). Prion formation was assessed by cell seeding experiments. Phosphotungstic acid 
(PTA)-extracted PrPres seeds -we denoted as PrPres the material generated by N2a cells 
transfected with 3F4-tagged H96Y MoPrP- were subjected to N2a cells and regularly passaged 
every 7 days up to P8. The detection of newly generated PrPres was assessed by PK digestion as 
previously described, and the PrPres seeds isolation using PTA was performed according to our 
previous protocols. 
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CHAPTER III 
 
 
 
RESULTS 
 
 
3.1 Identification of the structural determinant responsible for the interaction between 
PrPC and NCAM 
 
Among the variety of PrPC protein interactors, the neuronal cell adhesion molecule (NCAM) 
has been proved in vivo, but the structural basis of this functional interaction are still a matter of 
debate. Here we focused on the structural determinants responsible for human PrPC (HuPrP) and 
NCAM interaction using Stimulated Emission Depletion (STED) nanoscopy, surface plasmon 
resonance (SPR) and NMR spectroscopy approaches. 
PrPC co-localizes with NCAM in mouse hyppocampal neurons and this interaction is mainly 
mediated by the intrinsically disordered PrPC N-terminal domain, which binds with high affinity 
the NCAM fibronectin type-3 domain. NMR structural investigation revealed surface interacting 
epitopes governing the interaction between HuPrP N-terminus and the second module of NCAM 
fibronectin type-3 domain. Our data provided a molecular-level picture of the interaction 
between HuPrP and NCAM fibronectin domain, and revealed a new role of PrPC N-terminus a 
dynamic and functional element responsible for protein-protein interaction.  
 
3.1.1 NCAM co-localizes with PrPC 
Functional interactions of PrPC with its binding partner(s) have been suggested previously 
[218]: cis and trans interactions between NCAM and PrPC promote neurite outgrowth; the 
disruption of these interactions indicate that PrPC is involved in nervous system development 
cooperating with NCAM as a signaling receptor. 
We used STimulated Emission Depletion (STED) nanoscopy to confirm the association 
between PrPC and NCAM in mouse hippocampal culture. We determined simultaneously the 
cellular distribution of PrPC, NCAM and Actin (Fig. 3.1 A). PrPC and NCAM share very similar 
distributions along the neurite and in hippocampal growth cones (GC). The staining for PrPC and 
NCAM was preferentially localized in the central domain and transition zone of the GC 
membrane, when compared to the actin, rarely detecting these staining in motile structure like 
filopodia (Fig. 3.1 B).  
By using STED nanoscopy we could detect very low colocalization between PrPC and NCAM, 
while treatment with 1 µM nerve growth factor (NGF) results in an increasing of colocalization 
(Fig. 3.1 B). The observed higher association between PrPC and NCAM in treated cultures 
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suggested that these proteins might functionally cooperate to transduce signals into the cell 
interior, which in turn trigger the neurite growth. 
 
 
 
 
Figure 3.1. PrP-NCAM interaction in vitro. STED images of GC stained for PrP, NCAM, Actin and merge of 
the PrP and NCAM in control condition. Scale bar 500 nm. (A1-A2) High-resolution images of areas indicated in 
(A). Scale bar 250 nm. (B) As in (A) but neurons were incubated with 1 µM NGF (2 h). 
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3.1.2 FNIII1,2 domain binds to the HuPrP N-terminal domain with high affinity. 
SPR experiments were used to analyse the binding of FNIII1,2 domain to different HuPrP and 
MoPrP constructs, including full-length HuPrP and MoPrP (i.e. from residues 23 to 231 and 23-
230, respectively), the HuPrP N-terminal domain (residues 23-144) and the truncated C-terminal 
HuPrP and MoPrP (residues 90-231 and 89-230, respectively). We observed strong interaction 
between FNIII1,2 domain and the HuPrP N-terminal domain with Kd of 5.4 nM. Also the full-
length HuPrP binds to FNIII1,2 domain with high affinity (Kd of 337 nM) while for the 
truncated HuPrP we were not able to report any interaction. The full-length MoPrP displayed a 
week affinity for FNIII1,2 domain (Kd 3.8 µM), while the truncated MoPrP behaved almost 
identically to the truncated HuPrP, displaying no interaction with FNIII1,2 domain (Figure 3.2 
and Table 3.1).  
 
 
 
 
Figure 3.2. SPR analysis of the FNIII-HuPrP or MoPrP interactions. Shown are raw sensorgrams obtained on 
a Biacore 2000 instrument. Selected curves are labelled with the respective analyte concentration. Binding of full-
length HuPrP, HuPrP N-terminus and full-length MoPrP to immobilized FNIII (A, B and C, respectively). 
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Table 3.1. Dissociation constants for the interaction between FNIII (immobilized) and different HuPrP and 
MoPrP constructs. 
 
Protein Kd (nM) 
Kon 
(1/Ms) Koff (1/s) Chi2 
HuPrP(23-231) 337 2.00E+05 0.0674 0.629 
HuPrP(90-231) NO NO NO NO 
HuPrP(23-144) 5.4 1.42E+06 7.66E-03 0.612 
MoPrP(23-230) 3800 2.58E+04 0.0983 0.684 
MoPrP(89-230) NO NO NO NO 
 
 
Additionally, we confirmed that a short NCAM peptide, named BCL, corresponding sequence 
of residues 620-635 in FNIII1,2 domain is able to interact with HuPrP using ELISA (Figure 
3.3). Peptide BCL also binds to MoPrP [155] and it is considered a NCAM mimetic peptide 
employed as NCAM surrogate in pharmacological experiments [219]. These data add more 
insights about the HuPrP regions involved in the interaction with FNIII1,2 domain, showing that 
this binding is largely mediated by the largely unstructured N-terminal HuPrP domain. 
 
 
 
 
Figure 3.3. ELISA showing the interaction between BCL and full-length HuPrP. 
 
  
Immobilized: BCL 
Analyte: full-length HuPrP 
Antibody: SAF34 
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3.1.3 NMR structure of the NCAM fibronectin domain 2, FNIII2 
3.1.3.1 Sequence-specific resonance assignment of the FNIII2 
Binding properties of HuPrP and NCAM in solution were evaluated by performing NMR 
spectroscopy. Unambiguous assignment of HuPrP(23-144) residues was not possible because of 
high signal overlap in the 15N-HSQC spectrum, which was due to high percent of glycine 
residues, octarepeats and intrinsically disordered properties of unstructured N-terminus (Fig. 3.4 
A). Thus, studies with 15N, 13C isotopically labelled FNIII1,2, FNIII1 and FNIII2 domains were 
performed in order to find a suitable candidate to evaluate HuPrP-NCAM binding properties. 
 
 
 
 
Figure 3.4. (A) 15N HSQC spectra of HuPrP(23-144) and (B-D) FNIII1,2 domain at three different temperatures. 
 
 
15N HSQC spectra of FNIII1,2 domain were detected at three different temperatures. The 15N-
HSQC spectrum of FNIII1,2 domain was crowded with overlapped signals at 25 °C (Figure 3.4 
B). To improve relaxation features and cross peaks intensities in 15N-HSQC spectrum of 
FNIII1,2 domain the temperature of the sample was increased to 30 °C and 45 °C (Figure 3.4 C 
and D). While this approach resulted in a clear improvement of spectra resolution, on the other 
hand it caused the instability of the sample, leading to a complete protein precipitation. 
To characterized binding properties between HuPrP and NCAM, smaller module of FNIII1,2, 
FNIII1 and FNIII2 domains, were examined. The FNIII1 domain was also unappropriated for 
study because of sample instability. Thus, we employed the FNIII2 domain as a model system. 
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15N HSQC spectrum of 13C, 15N double labelled FNIII2 domain demonstrated good dispersion 
of cross-peaks indicating that the protein adopts a globular fold thus a potential for detailed 
structure characterisation (Figure 3.5 A). 
Sequence-specific assignment of the backbone resonances for FNIII2 domain was obtained 
using standard double resonance 15N-HSQC and triple resonance NMR experiments HNCO, 
HN(CO)CA, HNCA, HN(CO)CACB and HNCACB (See Figure 3.6 for the detailed spectra 
description). For side-chain assignments the protein was buffer exchanged in deuterated water to 
perform a 13C heteronuclear experiment (Figure 3.7). 1H and 13C resonances of aliphatic and 
aromatic side chains were assigned using 13C-HSQC and HAHB(CO)NH, CC(CO)NH, 
(H)CCH-TOCSY and 13C-edited HSQC-NOESY experiments (Figure 3.8). 
Final level of completeness of 1H, 13C and 15N resonance assignment was high (92.9%). Forty-
three chemical shifts were unassigned, most of them belonged to the C-terminal His-tag. 
 
 
 
 
Figure 3.5. Assigned 1H-15N HSQC spectrum of FNIII2 with one letter amino acid code. (A) A two-
dimensional HSQC spectrum of the FNIII2 is represented. The nitrogen chemical shifts are shown on the left side 
of the spectrum. (B) In this spectrum are visible cross-peaks for all N-H correlations. Mainly these are amide groups 
of protein backbone, with exception of prolines. The side chain NH2- groups of Asn and Gln are visible, usually in 
the right upper corner of the spectrum and the Trp side chain groups are also detected. 
 
 
 
 
 
 
 
 
 
A B
 
_____________________________________________________________________________ 
 
55
 
 
 
 
 
Figure 3.6. NMR sequence specific backbone assignment strategy. In the HNCA experiment the 
magnetization is transferred from 1H to 15N and then via the N-Cα J-coupling to the 13Cα and then back again to 15N 
and 1H hydrogen for detection. The chemical shift is evolved for 1HN as well as the 15NH and 13Cα, resulting in a 3-
dimensional spectrum. Since the amide nitrogen is coupled both to the Cα of its own residue and that of the 
preceding residue, both these transfers occur and peaks for both Cα are visible in the spectrum. However, the 
coupling to the directly bonded Cα is stronger, thus these peaks will appear with greater intensity in the spectra. In 
the CA(CO)NH spectrum the magnetization is passed from 1H to 15N and then to C’. From here it is transferred to 
13Cα and the chemical shift is evolved. The magnetization is then transferred back via C’ to 15N and 1H for 
detection. The chemical shift is only evolved for the 1HN, the 15NH and the 13Cα, but not for the C’. This results in a 
spectrum which is like the HNCA, but which is selective for the Cα of the preceding residue. In the CBCA(CO)NH 
spectrum magnetization is transferred from 1Hα and 1Hβ to 13Cα and 13Cβ, respectively, and then from 13Cβ to 13Cα. 
From here it is transferred first to C’, then to 15NH and finally to 1HN for detection. The chemical shift is evolved 
simultaneously on 13Cα and 13Cβ, so these appear in one dimension. The chemical shifts evolved in the other two 
dimensions are 15NH and 1HN. The chemical shift is not evolved on C’. Finally, in the HNCACB magnetization is 
transferred from 1Hα and 1Hβ to 13Cα and 13Cβ, respectively, and then from 13Cβ to 13Cα. From here it is transferred 
first to 15NH and then to 1HN for detection. Transfer form Cαi-1 can occur both to 15Ni-1 and 15Ni, or viewed the other 
way, magnetization is transferred to 15Ni from both 13Cαi and 13Cαi-1. Thus, for each NH group there are two Cα and 
Cβ peaks visible. The chemical shift is evolved simultaneously on 13Cα and 13Cβ, so these appear in one dimension. 
The chemical shifts evolved in the other two dimensions are 15NH and 1HN. 
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Figure 3.7. 1H-13C HSQC spectrum of FNIII2. This spectrum is the carbon equivalent of the 1H-15N-HSQC and 
it is a useful reference for side-chain assignments. All 1H-13C correlations are shown. The magnetization is 
transferred from 1H to 13C and then back again for detection and all 1H-13C moieties, regardless of chemical type, 
are showed. 
 
 
 
 
 
 
Figure 3.8. Side chain assignment strategy. 13C-HSQC aliphatic spectrum has been explained in the previous 
picture. Similarly, in the 13C-HSQC aromatic spectrum the magnetization is transferred from 1H to 13C and then 
back again for detection, and all 1H-13C moieties present in aromatic rings are showed. 
The assignment starts with a set of C(CO)NH spectra. In the CC(CO)NH spectrum the magnetization is 
transferred from the side-chain hydrogen nuclei to their attached 13C nuclei. Then isotropic 13C mixing is used to 
transfer magnetization between the carbon nuclei. From here, magnetization is transferred to the carbonyl carbon, 
onto the amide nitrogen and finally the amide hydrogen for detection. The chemical shift is evolved simultaneously 
on all side-chain carbon nuclei, as well as on the amide nitrogen and hydrogen nuclei, resulting in a three-
dimensional spectrum. Additional 3D experiments are obtained that are optimized for side chain spin connectivity. 
In the (H)CCH-TOCSY spectrum magnetization is transferred from the side-chain hydrogen nuclei to their attached 
13C nuclei. This is followed by isotropic 13C mixing and finally transfers back to the side-chain hydrogen atoms for 
detection. The proton resonances in aromatic ring are assigned using 3D 15N 13C HSQC-NOESY spectra. In these 
spectra magnetization is exchanged between all hydrogens using the NOE. Then the magnetization is transferred to 
neighboring 13C nuclei and back to 1H for detection. 
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3.1.3.2 Three-dimensional structure of FNIII2 
The structure modelling of FNIII2 domain was performed using program CYANA 3.0 [207]. 
Figure 3.9 shows iterative cycles of structure determination by extracting upper-distances from 
NOESY data sets, based on the CANDID algorithm.   
A high-resolution NMR structure of FNIII2 domain was determined on the basis of the high 
level of resonance assignments (92.9%) and in a total of 1658 NOE restraints. The root-mean-
square deviation (r.m.s.d.) values relative to the mean coordinates are 0.28 Å for backbone and 
0.78 Å for heavy atoms (residues 595-691). The complete structural statistics is summarized in 
Table 3.2. 
The calculated three-dimensional model showed that FNIII2 domain consists of six antiparallel 
β-strands, marked A-F on Figure 3.10. They are arranged into two right-handed β-sheets which 
formed a β-sandwich. The first β-sheet is composed of strands A and D (residues Ser616-
Asn620 and His657-Lys661, respectively) and the second β-sheet of strands B, C, E and F 
(residues Ile631-Ala640, Ile649-Pro652, Tyr669-Asn677 and Ala682-Phe687, respectively).  
 
 
 
Figure 3.9. Structures of FNIII2 obtained with the program CYANA.  
Cycle 1 Cycle 2 Cycle 3 Cycle 4
Cycle 5 Cycle 6 Cycle 7 Final structure
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Table 3.2. NMR restraints and structural statistics for the ensemble of 20 lowest energy structures of FNIII2 
domain.  
 
NOE upper distance limitsa  
Total 1658 
Intra-residue (|i-j| = 0) 337 
Sequential (|i-j| = 1) 441 
Medium-range (1 < |i-j| < 5) 108 
Long-range (|i-j| >= 5) 772 
Torsion angle restraints  
Backbone (j/y) 136 
RMSD to the mean coordinates (Å)  
Ordered backbone atoms (1-97) 0.28 ± 0.09 
Ordered heavy atoms (595-691) 0.78 ± 0.08 
Ramachandran plot (595-691)b  
Residues in most favored regions (%) 85.2 
Residues in additional allowed regions (%) 14.8 
Structure Z-scoresb  
1st generation packing quality -0.419 ± 0.568 
2nd generation packing quality 7.386 ± 2.149 
Ramachandran plot appearance -3.376 ± 0.339 
Chi-1/chi-2 rotamer normality -6.283 ± 0.259 
Backbone conformation -0.441 ± 0.137 
RMS Z-scoresb  
Bond lengths 1.201 ± 0.004 
Bond angles 0.581 ± 0.008 
Omega angle restraints 0.758 ± 0.030 
Side chain planarity 0.437 ± 0.029 
Improper dihedral distribution 0.779 ± 0.016 
Inside/Outside distribution 1.029 ± 0.011 
 
a None of the 20 structures exhibits distance violations over 0.2 Å and torsion angle violation over 5°.  
b Ensemble of structures was analysed by PROCHECK-NMR and WhatIF programs incorporated in CING 
structure evaluation package [209]. 
 
 
 
Figure 3.10. (A) Ensemble of 20 lowest energies structure of FNIII2 domain (residues 595-691). The β-strands 
are highlighted using letter codes. (B) Sequence of FNIII2 protein. The elements of secondary structure are shown. 
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3.1.4 NMR chemical shift perturbation analysis for characterizing the binding between HuPrP 
and NCAM 
Multidimensional heteronuclear NMR experiments were used to evaluate binding properties 
between the FNIII2 domain and N-terminal HuPrP(23-144) and to characterize the formed 
complex. Upon addition of HuPrP(23-144) the FNIII2 domain sample became blurred due to 
aggregation, leading to multimeric complex at pH 7.0. Interestingly, during the titration 
experiment no amide chemical shift changes Δδ(H,N) were observed in 15N-HSQC spectrum of 
FNIII2 domain (Figure 3.11). Detailed analysis of cross-peak line widths and absence of 
chemical shift changes gave the conclusion that cross-peaks correspond to unbound state of 
labelled FNIII2 domain. 
Analysis of signal intensities during the titration indicated that the cross-binding complex is 
formed in a 1:1 ratio. Additionally, we tried to thermally disrupt multimeric complex at 45 °C to 
gain monomeric form of the complex. While the sample cleared up indicating that the 
multimeres fell apart to smaller fragments, the 15N-HSQC spectrum did not improve after 
thermal treatment. Clearly, even smaller fragments of multimeric complex were still too big to 
be observed by NMR. Titration was replicated at pH 6.0 (Figure 3.12 A). Δδ(H,N) were 
observed in 15N-HSQC spectra of FNIII2 domain at ratio 1 to 0.5 for residues Arg599, Glu600, 
Gly614, Arg639, Ser642, Asp656, Ser664, Tyr669, Tyr672, Gln678, Lys683, His686 and 
Val688. However, the cross-peaks in 15N-HSQC spectra of FNIII2 domain disappeared at ratio 
1:2 due to complex formation similarly as observed at higher pH value.  
 
 
 
Figure 3.11. 15N HSQC spectrum of FNIII2 domain overlaid with 15N HSQC spectrum of FNIII2 domain 
titrated with HuPrP(23-144) peptide at pH 7.0. 
 
In order to determine the binding site on HuPrP, the N-terminal part of it was divided into 
smaller fragments. Graduate titrations of FNIII2 domain with peptides HuPrP(23-89), 
HuPrP(23-50), HuPrP(60-68), HuPrP(93-114) and HuPrP(93-114, P102L) were performed to 
the final ratio between protein and peptide 1 to 2 (Figure 3.12). Upon titrations with HuPrP(93-
114), HuPrP(93-114, P102L) and HuPrP(23-89) Δδ(H,N) were observed in 15N-HSQC spectra 
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of FNIII2 domain (Figure 3.12 C, E and F). In contrast, we did not identified any Δδ(H,N) of 
FNIII2 domain with peptide HuPrP(60-68) (Figure 3.12 B) and negligible one with peptide 
HuPrP(23-50) (Figure 3.12 D). For all titration studied were calculated Δδ(H,N) of FNIII2 
domain using equation 1. 
 
 
 
 
Figure 3.12. Overlays of 15N HSQC spectra of FNIII2 domain in the presence of peptides originating from 
HuPrP at pH 6. A, HuPrP(23–144). B, HuPrP(60-68). C, HuPrP(93–114). D, HuPrP(23-50). E, HuPrP(93–114, 
P102L). F, HuPrP(23-89).  The HuPrP peptide to FNIII2 equivalents are indicated with the corresponding spectra. 
 
 
Titrations with peptides HuPrP(23-144), HuPrP(23-89) and HuPrP(93-114, P102L) resulted in 
biggest Δδ(H,N) of FNIII2 domain. The biggest Δδ(H,N) were observed for residues Tyr669, 
Val673, His686, Phe687 and Val688 of FNIII2 domain.  Other cross-peaks of FNIII2 domain 
pH 6.0
FE
 
_____________________________________________________________________________ 
 
61
exhibit negligible chemical shift changes. Detailed analysis of Δδ(H,N) of FNIII2 domain 
presented in Figure 3.13 together with peculiarities of line-width broadening led us to conclude 
that residues Tyr669, Val673, His686, Phe687 and Val688 of FNIII2 domain are involved in 
interaction with HuPrP.  
 
 
 
 
Figure 3.13. Chemical shift changes Δδ(H,N) for FNIII2 domain upon interaction with peptides originating from 
HuPrP at pH 6.0. (A) HuPrP(23-144) peptide at ratio 1:0.5, (B) HuPrP(93-114, P102L) at ratio 1:2 and (C) 
HuPrP(23-89) at ratio 1:2. Δδ(H,N) were calculated according equation 1. 
 
 
Since peptide HuPrP(93-114, P102L) exhibited the strongest interactions with FNIII2 domain 
we examined the effects of interaction on the peptide as well. 15N-HSQC, NOESY, TOCSY, 
13C-HSQC aliphatic and aromatic spectra were used for chemical shift assignment of unlabelled 
peptide. 13C-15N ω1 filtered 2D NOESY/TOCSY and 13C-15N ω1 filtered 3D 15N-HSQC-NOESY 
were used to determine inter- and intramolecular contacts in complex. Upon binding no 
intermolecular contacts were observed in 13C-15N ω1 filtered 2D NOESY. The largest 
intramolecular chemical shift changes were observed for cross-peaks in 13C-15N ω1 filtered 2D 
TOCSY of amino acids Trp99, His111, Met112 and Ala113 of HuPrP(93-114, P102L). 
Experimental data therefore indicate that amino acids Tyr669, Val673, His686, Phe687 and 
Val688 of FNIII2 domain and Trp99, His111, Met112 and Ala113 of HuPrP(93-114, P102L) are 
most probably involved in the interaction of NCAM domain and wt HuPrP. This data was used 
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as docking restraints for HADDOCK calculation [220]. 131 lowest-energy structures were 
grouped into 13 clusters according to RMSD. The numbers of structures in the best 10 clusters 
varied from 4 to 34 with their HADDOCK scores ranged from 71.8 to 53.5. The clusters could 
be split into two groups of similar size. The first model describes interactions between Trp99 on 
HuPrP(93-114, P102L) and FNIII2 domain while the second one describes interactions of 
His111-Ala113 with HuPrP(93-114, P102L) and FNIII2 domain (Figure 3.14). 
 
 
 
 
Figure 3.14. Low-resolution model of complex between FNIII2 domain and HuPrP(93-114, P102L). (A) 
Ensemble of 40 models of complex between FNIII2 domain (pink) and HuPrP(93-114, P102L) (green and orange if 
it interacts with His111-Ala113 and W99, respectively) clustered by HADDOCK program (4 models from each of 
10 clusters). (B) Enlarged binding region of the best HADDOCK model of FNIII2 domain – HuPrP(93-114, 
P102L) complex. Amino acids involved in the interaction are presented with balls and sticks (FNIII2 domain in 
blue, HuPrP(93-114, P102L) in green). 
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3.2 Understanding the role of copper in prion conversion and susceptibility 
 
Copper coordination to the non-octarepeat region has garnered interest due to the possibility 
that this interaction may impact prion conversion. We used extended X-ray absorption fine 
(EXAFS) spectroscopy, cell-biology approaches and molecular dynamic (MD) simulations to 
study copper coordination at pH 5.5 and 7.0 in human PrPC constructs, either wild-type (WT) or 
carrying pathological mutations. 
 EXAFS spectroscopy is a powerful tool to investigate both local structure and dynamics on a 
wide class of metal-containing proteins. This technique is very sensitive to the coordination 
geometry of an absorbing atom and thus allows the measurement of bond distances and angles 
of the surrounding atomic cluster with atomic resolution, typically within 5 Å or less of the 
element of interest. Compared with diffraction-based methods, EXAFS generally does not 
provide three-dimensional information, but it can provide improved precision in atomic 
positions and it can also provide structural information on solutions. 
We show that mutations and pH cause modifications of copper coordination in the non-
octarepeat region. In the WT at pH 5.5, copper is anchored to His96 and His111, while at pH 7, 
it is coordinated by His111. Pathological point mutations alter the copper coordination at acidic 
conditions where the metal is anchored to His111. 
As model systems for the mutants we used Q212P, P102L –the prototypical GSS mutation 
[221]- and H96Y –an artificial mutation devoid of one His residue involved in copper binding. 
EXAFS data clearly highlighted modifications of the non-OR copper-binding site induced by 
these mutations. 
To understand the physiological implications of our EXAFS data, we performed in vitro and 
cell-based approaches. We found that H96Y mutation largely promoted prion conversion, PrP 
accumulation in the endosomal compartments, and generation of bona fide infectious prion 
material (e.g. displaying partial PK-resistance and the ability to perform seeded aggregation in 
vitro and in cell). 
Finally, MD simulations were used to hypothesize possible structural consequences on the 
HuPrP structure caused by an altered copper coordination in the non-OR region. In our 
simulations we predicted structural facets of WT HuPrP(90-231) coordinating Cu(II) via either 
H111 or both H96 and H111. Comparison of trajectories showed that removal of H96 ligand 
from the Cu(II) coordination results in β-sheet enrichment in the segment spanning the non-OR 
region and palindromic motif.  
Our study highlights the importance of the non-OR region for prion conversion and proposes a 
model in which PrPC coordinating copper with one His residue may render PrPC more prone to 
prion conversion at acidic pH condition. 
 
3.2.1 Copper coordination in the non-OR region of WT HuPrP 
A previous investigation XAS was used to determine the atomic structure of non-OR copper-
binding site in the WT HuPrP(90-231) [164]; in this thesis work XAS experiments at the Cu K-
edge were carried out at pH 5.5 and the structure of the binding site of both Cu(II) and Cu(I) was 
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found to be identical. Quantitative analysis of the EXAFS spectra indicated that in both 
oxidation states, copper ion is coordinated by two His residues (H96 and H111 with Cu-N 
distance of 1.98(2) Å), by two low Z ligands (either oxygen or nitrogen atoms at 1.98 (1.99) Å) 
and by one sulphur scatterer at longer distance (i.e. 3.25 Å) [164]. 
To highlight the effect of pH on the local coordination of the copper ion, XAS spectra of both 
Cu(II) and Cu(I) HuPrP(90-231) complexes were collected at pH 7.0 (Figure 3.15). While at pH 
5.5 the EXAFS spectra are almost identical for both copper oxidation states, at pH 7.0 EXAFS 
signals show markedly different features over the full k-range. The quantitative analysis of the 
EXAFS data indicates that at pH 7.0 only a single His coordinates the metal ion in both 
oxidation states, thus suggesting that one of the two His residues (H96 or H111) moves away 
from the metal. 
EXAFS data concerning Cu(II)-HuPrP(90-231) at pH 7.0 could be modeled as a four 
coordinate copper center with one His at 1.99(2) Å, and three N/O scatterers at 1.99(4) Å with a 
more distant sulphur scatterers at 3.47(4) Å. As far as the Cu(I)-HuPrP(90-231) protein is 
concerned, the EXAFS analysis revealed a three-fold coordination with one His at 1.98(2) Å, 
one N/O scatterers at 2.00(2) Å and one sulphur scatterer at 2.27(4) Å. In this case one Met 
residue enters the Cu(I) first coordination shell, similarly to what previously found at acidic pH 
value [164]. 
 
 
Figure 3.15. Copper coordination in the non-OR region of WT and H96Y HuPrP. k3-weighted EXAFS 
spectra and Fourier transforms of the experimental data of Cu(II) and Cu(I) bound to WT HuPrP(90-231) at pH 5.5 
and 7.0. 
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3.2.2 Copper coordination in H96Y, P102L and Q212P HuPrP mutants  
The Cu(II) local coordination structure in the H96Y mutant was investigated both at pH 5.5 
and 7.0 values. At pH 5.5, the Cu K-edge EXAFS data for H96Y, compared to the WT protein, 
exhibited a clear modification in the coordination environment. This variation is explained by 
the existence of a single His in the non-OR region of the H96Y mutant, hampering the 
coordination of the Cu(II) ion with two His residues (Figure 3.16). Conversely, at pH 7.0 the 
EXAFS spectra of the H96Y mutant and WT proteins are almost identical, thus suggesting that 
H111 is involved in the copper binding site in both cases. In addition, the EXAFS data showed 
that the H96Y mutant maintains the same coordination environment around the Cu(II) ion when 
increasing pH from 5.5 to 7.0. The analysis of the EXAFS data revealed the presence of a four 
coordinate copper center almost identical to that of the WT protein at pH 7.0, with the H111 
residue at 2.00 (2) Å from the ion (Appendix I, Table S1). The structures of Cu(II) and Cu(I) 
binding sites were also investigated in Q212P and P102L HuPrP mutants at both pH 5.5 and 7.0 
values (Figure 3.17 A-B). The EXAFS data of the mutants share the same coordination pattern 
observed for the WT at pH 7.0, where the copper ion is coordinated by a single His, namely 
H111 (Appendix I, Table S1). In conclusion, while in the WT the copper ion -at both oxidative 
states- changes coordination losing the contact with H96 at pH 7.0 (Figure 3.17 C), in the 
mutants copper is bound only to H111 independently of the pH (Figure 3.17 D).  
 
 
 
 
Figure 3.16. Copper coordination in the non-OR region of H96Y HuPrP. k3-weighted EXAFS spectra and 
Fourier transforms of the experimental data of Cu(II) and Cu(I) bound to WT HuPrP(90-231) at pH 5.5 and 7.0 (A), 
and of Cu(II) bound to WT HuPrP(90-231) and H96Y at pH 5.5 and 7.0 (B). 
Cu(II) pH 7.0
A B
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Figure 3.17. Comparison between copper K-edge experimental data of pathological Q212P, P102L and WT 
HuPrP. k3-weighted EXAFS spectra and Fourier transforms of Cu(II) and Cu(I) bound to WT HuPrP(90-231) and 
Q212P at pH 5.5 and 7.0 (A) and of Cu(II) and Cu(I) bound to WT HuPrP(90-231) and P102L at pH 5.5 and 7.0 
(B). Schematic representations of copper binding sites in the WT HuPrP(90-231) (C) and in the mutants (D) at both 
pH 5.5 and 7.0. Green spheres identify a single cupper ion at both oxidative states. 
 
 
3.2.3 The H96Y mutation promotes prion conversion in neuroblastoma cells 
The observed structural differences in the copper coordination among WT and pathological 
mutants at pH 5.5 may have relevant physiological implications since this alteration in the 
copper binding site might trigger PrPC to PrPSc conversion. Hence, the non-OR region could be 
an important “hot spot” for prion conversion. 
We first investigated the effect on prion replication of single His residues along the entire N-
terminal PrPC domain. ScN2a cells were transiently transfected with 3F4-tagged WT and mutant 
MoPrP constructs in which each individual His located inside the OR and non-OR copper 
binding sites were substituted by Tyr, thus abolishing the physiological copper binding. The 
introduction of the 3F4-epitope tag into these constructs makes it possible to discriminate 
between transfected and endogenous PrPC. His to Tyr substitutions in MoPrP did not affect the 
total PrP expression levels (Figure 3.18 A-B).  
The enhanced resistance to protease digestion is a primary feature to discriminate between 
PrPSc and PrPC in cells chronically infected by prions. The PK digestion profiles showed 
remarkably different PrPSc levels among the mutants. While other mutants in the OR region 
A B
C D
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displayed negligible PK-resistant PrPSc levels similar to the WT, the H96Y mutant yielded a 
significantly higher PK-resistant PrPSc signal, providing a first evidence for the role of H96Y 
mutation in prion conversion (Figure 3.18 A-B). 
 
 
 
Figure 3.18. The non-OR H96Y mutation promotes prion conversion in ScN2a cells. (A) Fifty µg of 
undigested lysates from ScN2a cells expressing 3F4-tagged WT and mutated MoPrPs was applied to each lane. 
Five hundred µg of cell lysate was digested with PK (20 µg/mL) at 37oC for 1 hour. MoPrPs were detected by anti-
PrP 3F4 antibody. β-actin was used as internal loading control. Arrows (▼) indicate positions on the gels where the 
blots have been cropped. (B) Quantitative analysis of total PrP expression and PrPSc PK-resistance levels in 
transfected constructs (n = 4, **P< 0.005, by two-tailed t test).  
 
 
Because H96 binds copper, it is likely that the removal of this copper ligand might render PrPC 
more prone to the conversion in ScN2a cells. Consequently, the absence of copper from the non-
OR region could promote this pathological process. To verify this hypothesis, we measured the 
PrPSc PK-resistance levels in ScN2a cells transfected either with WT or H96Y MoPrP and 
treated for 48 hours with cuprizone (CPZ), a well known selective Cu(II) chelator that does not 
affect cell viability and cannot cross plasma membranes[222]. CPZ treatments on WT ScN2a 
cells promoted a significantly increase of PrPSc-PK resistance levels upon 10 to 40 µM CPZ 
additions, suggesting that PrPC in the apo form is more susceptible to PrPSc conversion (Figure 
3.19 A-B). The PrPSc levels remained a plateau among control and CPZ-treated H96Y ScN2a 
cells (Figure 3.19 A-B) but always higher than PrPSc level in the WT cells as also previously 
presented (Figure 3.18 A-B). These data are consistent with the hypothesized mechanism 
whereby H96Y mutant is per se sufficient to generate high amount of PrPSc molecules. Copper 
appeared as a pivotal modulator of this process since its absence from PrPC side seems to 
promote prion conversion. 
 
 
40
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Figure 3.19. The non-OR H96Y mutation promotes prion conversion in ScN2a cells. (A) Copper chelation 
promoted increased PrPSc formation in 3F4-WT transfected ScN2a cells. CPZ, cuprizone. Full-length blots are 
presented in the Supplementary Figure S4c-e. (B) Quantitative analysis of PrPSc PK-resistance levels in 3F4-WT 
and 3F4-H96Y MoPrP transfected ScN2a cells treated with 10 µM CPZ (n = 3, **P< 0.005 and *P< 0.05). 
 
 
3.2.4 Biochemical properties of H96Y mutant 
We then investigated whether purified PrPSc from H96Y ScN2a cells shares biochemical 
properties typical of natural prions, including features such as templating the β-sheet conversion 
of new PrP molecules, partially PK-resistance, positivity to ThT and ThS staining, cell-to cell 
transmissibility and intracellular accumulation. We therefore evaluated these properties in vitro 
and in cell-based experiments. 
By means of amyloid seeding assay, PTA-isolated PrPSc seeds from ScN2a cells expressing 
H96Y mutant were used to promote the conversion of recombinant full-length WT MoPrP. 
Differently from the WT-PrPSc seed, we found that the addition of the H96Y-PrPSc seed 
significantly promoted MoPrP fibrillization reactions at both pH 5.5 and 7.0 values, resulting in 
ThT positive kinetics with shorter lag-phases than the controls (Figure 3.20 A-B).  
 
 
 
Figure 3.20. The non-OR H96Y mutation promotes prion conversion in ScN2a cells. (A) ASA showing the 
kinetics of MoPrP fibrillization in the presence WT and H96Y-PrPSc seeds at pH 5.5 and 7.0 and (B) the 
corresponding mean value of the lag phases in hours (n = 4, *P< 0.05).  
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To test the hypothesis that H96Y mutant causes prion formation in non-prion infected cells, 
N2a cells were transfected with 3F4-WT or H96Y mutant MoPrP and regularly passaged. We 
found immunoreactive mildly PK-resistant PrP bands –denoted as PrPres or bona fide PrPSc in 
the absence of in vivo assays- starting from passage (P) 4 to P8 (Figure 3.21 A). The isolated 
H96Y-PrPres material observed in P8 was then used as infectious seed in new N2a cells regularly 
passaged up to P8 (Figure 3.21 B). Interestingly, we observed an increment in PrPres levels over 
passages, thus indicating that H96Y-PrPres seeds induced de novo conversion of endogenous 
PrPC to PK-resistant PrP material (Figure 3.21 C). 
Subsequently, we evaluated whether N2a cells transfected with H96Y mutant displayed 
tinctorial features reminiscent of PrPSc. By using Thioflavin-S (ThS), a specific dye for staining 
in cells the protein aggregates enriched in amyloid motifs, we found ThS-positive cytoplasmic 
H96Y mutant deposits similarly to ScN2a (Figure 3.21 D). 
 
 
 
 
 
Figure 3.21. Biochemical properties and cellular localization of H96Y mutant in N2a cells. (A) The H96Y 
mutant displays mild PK-resistance when expressed in N2a cells regularly passaged every 7 days up to passage (P) 
8. Cell lysates were treated with 2 or 5 µg/mL of PK. Two exposures of the same blot are shown (Faint: 30 sec 
exposure; Dark: 6 min exposure). PrPs were detected by anti-PrP 3F4 antibody. β-actin is used as internal control. 
Arrows (▼) indicate positions on the gels where the blots have been cropped. (B) Schematic representation of the 
seeding experiment in N2a cells. (C) PTA-extracted PrPSc from N2a cells transfected with 3F4-H96Y MoPrP were 
inoculated into N2a cells and regularly passaged every 7 days up to P8. The PrPres detection was assessed by PK 
digestion (5 µg/mL) through passages. (D) ThS-positive H96Y MoPrP aggregates detected in N2a cells. The cells 
were stained for PrP expression (red) and ThS (green). Untransfected N2a and ScN2a cells (mock) were used as 
controls. Scale bar: 12 µm. 
A
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The observation that the H96Y mutant forms ThS-positive aggregates demands the 
identification of the primary intracellular compartments where H96Y mutant accumulation 
occurs. Consistent with previous studies, 3F4-WT MoPrP was found mostly on the cell surface 
and it was detectable along the ER, endosomal and lysosomal compartments. The WT and 
H96Y showed co-localization with the ER marker calnexin indicating a correct trafficking 
through the ER (Figure 3.23 A). Biochemical analysis on transfected WT and mutant MoPrP 
showed that the proteins display the same glycosylation patterns and molecular weight after 
Endo-H and PNGase-F treatments (Figure 3.22). However, we found a significant population of 
H96Y mutant co-localizing with organelle markers as EEA1 (early endosomes), Tfn (recycling 
endosomes), M6PR (late endosome) and LAMP2 (lysosome marker) (Figure 3.23 B), 
suggesting a predominant accumulation of the mutant in the acidic compartments, as reported in 
previous studies on PrPSc intracellular accumulation. 
 
 
 
Figure 3.22. The OR and non-OR mutations share the same glycosylation patterns and proteolytic features when 
treated with Endo-H and PNGase-F as the WT MoPrPC. The positions of diglycosylated, monoglycosylated and 
unglycosylated forms (denoted as di, mono and un) of PrPC are on the right of each WB. PrPs were detected by 
anti-PrP 3F4 antibody. 
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Figure 3.23. The H96Y MoPrP mutant displays intracellular accumulation in the endosomial 
compartments. PrP localization in N2a cells expressing the 3F4-WT MoPrP (A) or H96Y MoPrP (B). Nuclei are 
labeled with DAPI (blue), PrPs are detected by 3F4 antibody (green); organelle markers, such as Calnexin (ER 
marker), EEA1 (early endosomes marker), Tfn (recycling endosome marker), M6PR (late endosome marker) and 
LAMP2 (lysosome marker) are labeled in red. Insets in (B) shows a magnification of the merged panels (white 
boxed areas). Scale bars: 12 µm. 
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3.2.5 Removal of the H96-Cu(II) bond creates transient N-terminal β-sheet structures 
To interpret our results from a structural biology point of view, we performed MD simulation 
studies to predict the structural facets of WT HuPrP(90-231) coordinating Cu(II) either with 
His96 and His111 or with His111, termed 2His and 1His models, respectively.  
The removal of H96 from the Cu(II) coordination sphere did not produce significant changes 
in the globular domain (residues 128-231), showing similar α2-α3 helix orientation as suggested 
by previous MD and NMR studies[25, 223] (e.g. α2-α3 helix angle is 51.2° and 49.1° in 2His and 
1His models, respectively, while it is 50.9° in NMR structure) (Figure 3.24 A). While the C-
terminal domain in the two simulation models featured a comparable flexibility (residue-wise 
Root Mean Square Fluctuation), the N-terminal segment of the 2His model displayed higher 
flexibility, particularly between residues 98-102 and 116-123 (Figure 3.24 B and Figure 3.25 
A). Additionally, the 2His trajectory yielded a slightly higher radius of gyration as compared to 
the 1His (1.77±0.08 nm vs 1.74±0.04 nm) with more pronounced oscillations (Figure 3.25 B) 
confirming that the N-terminal segment in the 2His trajectory was relatively more disordered. 
 
 
 
 
 
 
Figure 3.24. The ion coordination sphere affects HuPrP(90-231) dynamics in MD simulations. (A) 
Superimposition of average structures sampled in the 2His and 1His trajectories. Helical domains are represented in 
blue and red in 2His and 1His, respectively, the β1 and β2 sheets are in yellow, coils are represented in gray (2His) 
and orange (1His); the non-OR regions are depicted using a wider transparent ribbon. (B) Root Mean Square 
Fluctuation (RMSF) of residues for the 2His and 1His simulations. RMSF was calculated fitting the coordinates of 
the complete protein (2His: green dot-dashed line; 1His: blue dotted line) or restricted to the C-terminal domain 
(2His: black line; 1His: red dashed line). In both simulations the N-terminal domain is, as expected, much more 
BA
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flexible with the exception of residues 226-231; the 2His simulation apparently features greater fluctuations but the 
differences fade out when only the stable C terminal domain is considered. Notable exceptions are residues H140 
and R151. (C) Residue-wise β-sheet content for the 2His and 1His simulation as a percentage of sampling (150.0 
ns); the 1His simulation shows unstable β-sheet formation between residues 106-109 and 114-117 (also shown in 
the inset). (D) Comparison of the first centroid obtained by clustering the N-terminal domain Cα atoms in the 2His 
(left) and 1His (right) simulations; residues 106-109 and 114-117 are shown in ball and stick (backbone is shown in 
magenta as in Figure 3.25 A); copper binding residues H96, Q98 and H111 are shown as sticks and the copper ion 
as a dark green sphere (note that M109 belongs to both groups); a number of residues forming hydrogen bonds 
unique to one system are explicitly labeled to improve clarity. 
 
  
 
 
Figure 3.25. (A) Cartoon representation of RMSF. Ribbon width is proportional to fluctuations; the coordinates 
correspond to those of the first centroid obtained for each trajectory by cluster analysis of the C-terminal domain. 
The ratio between radius and RMSF is the same in the two models. The average relative orientation of residues 106-
109 and 114-117 (colored in magenta) in the 1His system is also clearly observable. (B) Radius of gyration (Rg) 
calculated for the 2His (black) and 1His (red) trajectories. The Rg of the 2His trajectory features transitions between 
different conformation with Rg up to 2 nm with a lifetime of several nanoseconds each while the Rg of the 1His 
simulated is stably oscillates around 1.74 nm. 
 
 
The reduced flexibility of the residues 90-120 segment observed in the 1His trajectory is 
attributed to the presence of novel hydrogen (H)-bonds and salt bridges, which were uniquely 
present in the 1His simulation. In particular, we observed that in the 2His system the side-chain 
of T95 formed H-bond in 89% of sampling with the backbone oxygen of T107, the backbones of 
T95 and P105 formed a H-bond for 92% of sampling and the side-chains nitrogen atom of Q98 
(a residue involved in copper binding) and N100 formed a H-bond in 51% of sampling. In the 
1His trajectory, the backbones of residues N108 and A116 formed H-bond in 58% of sampling 
and the oxydryl group of T107 bound to the backbone of P105 in 62% of sampling. These 
alterations of the internal hydrogen bond networks in the 1His system created favorable 
conditions for transient β-sheet motif formations in the segments formed by residues 106-109 
and 114-117 (with a lifetime between 20% and 30% of sampling) which were not observed in 
the 2His trajectory (Figure 3.24 C and Figure 3.25 A). 
A cluster analysis was performed on the N-terminal domain (residues 90-121) of the 2His and 
1His trajectories, using 15000 even spaced configurations. More than 80% of the configurations 
in both trajectories were included in the first cluster (12017 for 2His and 13347 for 1His, 
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respectively). Comparison of the first centroid structures obtained from the 1His and 2His 
simulations (Figure 3.24 D) shows that in the former case these groups of residues are indeed 
roughly antiparallel, with the side-chains of residues 106-109 oriented towards the backbone of 
residues 114-117, i.e. in a favorable position for the formation of a small β-sheet. On the other 
hand, in the 2His trajectory these two clusters form an angle of approximately 90° in most of the 
sampled structures. 
 
 
3.2.6 Copper coordination in the non-OR region of prion resistant species 
The Cu(II) local coordination structure in the OvPrP ARR and OpPrP has been investigated by 
X-ray absorption spectroscopy (XAS) at pH 5.5. The EXAFS experimental spectra of these two 
species are almost identical (Figure 3.27 B-C) indicating a similar coordination environment of 
copper in OvPrP ARR and OpPrP. As showed in the OpPrP amino acidic sequence (Figure 
3.26) H96 (here in human numbering) is replaced by Y96, therefore only one His residue can 
coordinate the Cu(II) ion. This result is confirmed by the EXAFS spectra showing markedly 
different features in the k range around 5 Å-1 which is sensitive to the His ligands, as compared 
to WT HuPrP. Additionally, the intensity of the peaks in the region between 2 and 4 Å of the FT 
spectra of OvPrP ARR and OpPrP (Figure 3.27 E-F) is lower compared to WT HuPrP; this 
result is compatible with a coordination with one His and an additional amino acidic residue that 
is chelated to the Cu(II) ion [217]. Note that H96 is present in OvPrP ARR but the EXAFS 
spectrum of this species is different from that of WT HuPrP, indicating that the Cu(II) ion has a 
different coordination structure. 
 
 
 
Figure 3.26. Amino acid sequences of HuPrP, OpPrP, OvPrP and BvPrP. Comparison of amino acid 
sequences and secondary prion protein structure of human (HuPrP; Homo sapiens, GenBank accession number 
AAH22532), opossum (OpPrP; Monodelphis domestica, 001035117), ovine with the polymorphic residue position 
(Q/R) (OvPrP; Ovis aries, AFM91142) and bank vole (BvPrP; Myodes glareolus, AAL57231). At the top, the 
secondary structure elements are shown. The yellow box highlights the non-OR copper binding site (residues 90-
111) and the green box the β2-α2 loop (residues 163-172). 
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Figure 3.27. Copper coordination in the non-OR region of WT HuPrP, OvPrP ARR and OpPrP. Cu K-edge 
EXAFS experimental data of (A) Cu(II)-bound WT HuPrP, (B) Cu(II)-bound OvPrP ARR and (C) Cu(II)-bound 
OpPrP. Non phase-shift-corrected Fourier transforms of the experimental data of (D) Cu(II)-bound WT HuPrP, (E) 
Cu(II)-bound OvPrP ARR and (F) Cu(II)-bound OpPrP calculated in the interval k 2.1-10.0 Å-1. 
 
 
By comparing the amino acidic sequence of OpPrP and OvPrP ARR (Figure 3.26) whose 
EXAFS spectra are equal (Figure 3.27 B-C), it is evident that only S95 is present in both 
systems and it is the only possible ligand of the Cu(II) ion. Starting from these observations a 
quantitative analysis of the EXAFS data has been carried out using a coordination model around 
the Cu(II) ion comprising one His, one Ser and one Gln in the equatorial plane. The Ser ligand is 
chelated to the Cu(II) ion through two oxygen atoms forming a 6-fold ring [217]. This geometry 
gives rise to multiple scattering (MS) contributions that increase the intensity of the FT higher 
distance peaks. The fitting procedures applied to the OvPrP ARR and OpPrP EXAFS spectra 
produced a very good agreement between the theoretical and experimental signals (Appendix I, 
Figure S1 A-B) and the structural parameters obtained from the minimization procedures are 
listed in Appendix I, Table S2. For both OvPrP ARR and OpPrP the EXAFS analysis reveals 
the existence of a distorted octahedral geometry of the copper center with H111, S95 and Q98 
placed in the equatorial positions, and M109 and an oxygen scatterer in the axial sites. We 
denoted this Cu(II) coordination geometry in OvPrP ARR and OpPrP as type-1 where the 
copper is tetra-coordinated by Ser, Gln, Met and His residues. Å. A pictorial description of this 
coordination geometry is shown in Figure 4.3. 
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3.2.7 Copper coordination in the non-OR region of prion susceptible species 
The copper coordination was investigated by means of XAS in two susceptible mammalian 
species, namely OvPrP VRQ and BvPrP. The EXAFS and FT experimental spectra of these 
systems are similar to those of HuPrP Q212P (Figure 3.28) and the low intensity of the second 
peak of the FT suggests that only one His residue coordinates the Cu(II) ion. 
The EXAFS data analyses of OvPrP VRQ and BvPrP have been carried out using the 
coordination geometry determined for HuPrP Q212P. Also there is agreement between the 
theoretical and calculated spectra (Appendix I, Figure S1C-D), the full list of structural 
parameters obtained from the minimization procedures is reported in Table S1. The EXAFS data 
analysis shows the existence of a four-coordinated copper center with one His at 2.00(2) Å, one 
Gln at 1.99(2) Å, one water molecule at 2.41(3) and one Met at 3.26(4) Å. A pictorial 
description of this coordination geometry, denoted as type-2, in the susceptible mammalian 
species is shown in Figure 4.3. 
 
 
 
 
Figure 3.28. Copper coordination in the non-OR region of HuPrP Q212P, OvPrP VRQ and BvPrP. Cu K-
edge EXAFS data of (A) Cu(II)-bound HuPrP Q212P, (B) Cu(II)-bound OvPrP VRQ and (C) Cu(II)-bound BvPrP. 
Non phase-shift-corrected Fourier transforms of the experimental data of (D) Cu(II)-bound HuPrP Q212P, (E) 
Cu(II)-bound OvPrP VRQ and (F) Cu(II)-bound BvPrP calculated in the interval k 2.1-10.0 Å-1. 
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CHAPTER IV 
 
 
 
DISCUSSION 
 
 
The conversion of the cellular prion protein PrPC into the infectious isoform (PrPSc) is the key 
event in prion diseases. The physiological role of PrPC, as well as the structural and molecular 
mechanisms leading to PrPSc conversion, remains one of the greatest gaps in our knowledge of 
the prion field. Putative roles for PrPC are based on its localization in the central and peripheral 
nervous systems and on PrPC-interacting molecules or metal ions through its unstructured N-
terminal domain. 
In the present section, results aimed to analyze the interaction between PrPC and NCAM and 
PrPC with copper ions will be discussed. 
 
 
4.1 Identification of the structural determinant responsible for the interaction between 
PrPC and NCAM 
 
Among the variety of PrPC protein interactors [34], PrPC associates with NCAM in vivo. Both 
molecules have been independently implicated in nervous system development and may play a 
role in neural stem cells [224, 225]. PrPC recruits to and stabilizes the transmembrane NCAM 
isoforms (NCAM-180 and NCAM-140) in lipid-rich microdomains. This activates FYN kinase 
and promotes neurite outgrowth by cis and trans interactions [218, 226]. The interaction of these 
two molecules and their relation to specific signaling pathways during neurodevelopment merits 
further investigation at the structural and molecular level, not the least because the physiological 
role of PrPC may provide novel insights into the neuropathology of prion diseases. In line of this, 
the structural basis of the cross-talk between PrPC and NCAM has not been previously 
investigated. 
In this thesis work, we have performed a structural investigation on the interaction between the 
recombinant FNIII2 domain of NCAM and different peptides originating from N-terminal 
human PrPC using different experimental approaches.  
The in vitro experiments designed to confirm the co-localization of PrPC and NCAM in 
hippocampal neuron cultures led us toward a better understanding of this interaction. We have 
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identified the HuPrP and MoPrP segments able to interact with the FNIII1,2 domain by means 
of SPR experiments. These experiments have unveiled that the N-terminal HuPrP domain 
mediates the FNIII1,2 domain binding with high affinity.  
X-ray approaches have been previously applied to better understand the structural properties of 
the FNIII1,2 domain [227]. Interestingly, the comparison between the FNIII2 NMR structure 
and the corresponding x-ray structure revealed local structural differences in the length of b-
strands. Although the NMR structure features two short b-strands (A and D) on one protein side 
and four b-strands (B, C, E, and F) on the other, the x-ray structure is characterized by seven 
strands (Figure 4.1). Structural discrepancies between diffraction and NMR data are to be 
expected considering the differences of the two methods in terms of spatial distribution of the 
molecules in the sample and time scales accessible to each method. Notably, solution NMR data 
represent an average over semi-randomly oriented molecules in solution detected in a 
nanosecond-to-second time regime, whereas diffraction data represent an average over 
molecules arranged in a periodic crystal lattice acquired in a seconds time scale.  
 
 
 
 
Figure 4.1. Structural comparison between the NMR structure of FNIII2 (in yellow, PDB id 5LKN) and the 
corresponding X-ray structure (in blue, PDB id 2VKW). In A the superimposition of the two 3D structures; in B 
the secondary structure comparison with highlighted the name of the β-strands used for the NMR structure of 
FNIII2 and the correspodnding amino acid sequence. 
 
A
B
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We have performed NMR experiments designed to identify the binding sites on the FNIII2 
domain and HuPrP N-terminus responsible for the interaction. The implications of our findings 
are important in prion biology as we provide the first structural evidence that NCAM mediates 
the interaction with the N-terminal domain of HuPrP through its FNIII1,2 domain. We propose a 
model where this largely unstructured segment acts as a dynamic element able to recruit NCAM 
molecules and to mediate physiological processes. We found that the WT HuPrP mediates 
binding with the FNIII2 domain via its N-terminal segment (residues 23–144). Interestingly, the 
N terminus contains a glycosaminoglycan (GAG)-binding motif. The binding of GAG is 
important in prion diseases. This idea is supported by evidence that mutant recombinant PrP 
binds more GAG, which promotes the aggregation of mutant recombinant PrP more efficiently 
than HuPrP wild type [228]. Thus, these data corroborate the idea that besides binding metal 
ions and GAG, the N-terminal domain also mediates cis interactions with the NCAM fibronectin 
domain.  
As opposed to WT HuPrP, the P102L mutant seems to possess an extra binding site localized 
in the segment 93–114, also denoted as the non-octarepeat copper-binding site [164, 216]. 
Peptides HuPrP(93–114) and HuPrP(93–114, P102L) have the same position in HuPrP N 
terminus except for the proline-to- leucine substitution at residue 102. Comparison of the (H,N) 
values for the FNIII2 domain after titration with both HuPrP(93–114) and HuPrP(93–114, 
P102L) led to a conclusion that the interaction of the latter with the FNIII2 domain is stronger. 
Thus, we argue that P102L mutation may affect binding with the FNIII2 domain, presumably 
leading to a stronger interaction with NCAM, which in turn may lead to abnormal Src family 
kinase activation. 
These findings about the interaction between HuPrP and NCAM may have biological 
relevance on prion conversion. Different compounds, including antibodies or chemical drugs, 
with high affinity for PrPC have been employed as candidates for therapeutic approaches aimed 
at inhibiting prion replication. This approach postulates that any PrPC ligand acts as molecular 
chaperone able to stabilize the protein folding, thus limiting the conversion to PrPSc. NCAM 
does not play a direct role during prion formation as observed in NCAM knock-out mice 
showing the same incubation period when compared with wild-type mice infected by prions 
[150]. It is plausible that any interference with NCAM-mediated signaling in the diseased brain 
may favor cell death and inhibit synaptic plasticity. The interactions between PrPC and NCAM 
could therefore be reduced by accumulation of PrPSc in the diseased nervous system. Thus, it is 
conceivable that the association of NCAM to PrPC favors functional signaling pathways through 
FYN, which is also implicated in synaptic functions. Furthermore, PrPC-NCAM crosstalk is 
crucial for the coordinated regulation of cell cycle progression and the differentiation of 
neuronal precursors toward different neuronal phenotypes [229]. We found that this interaction 
is mediated by the PrPC N-terminus, particularly in the segment from residues 23 to 50 includes 
four positively charged residues (i.e. KKRPK) known to play a role in the PrPC endocytic 
trafficking and in its localization to lipid rafts [17, 230]. Our study suggests that the interaction 
between residues 23–50 and the NCAM fibronectin domain may determine the fate of PrPC in 
the cell surface raft domain. Here PrPC participates in the complex molecular networks and 
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signaling mechanisms, both cell-intrinsic and cell-extrinsic, that influence cell fate and 
differentiation. It is worth nothing that involvement of other PrPC N-terminus regions in the 
binding with NCAM cannot rule out. 
The mechanisms that recruit and assemble different trans-membrane signaling molecules to 
distinct membrane sub-domains have only started to emerge. In these environments, signaling 
and scaffolding proteins can self-associate and form dimeric or multimeric assemblies. Protein 
dimerization has been reported as a common mechanism to cluster downstream signaling 
components and thereby enhance the signaling cascade [231]. According to a recent model, 
NCAM is present on the cell surface as cis dimers, formed by the interactions between the Ig1 
and Ig2 domains [148, 232]. The role of cis dimerization in NCAM dimerization is debated, but 
it is a pre-requisite for NCAM clustering on the cell surface, which in turn results in cell-cell 
adhesion via trans interactions between NCAM clusters.  
These data increase the evidence that the largely unstructured N-terminal domain acts as 
dynamic element able to recruit molecules, i.e. NCAM, and to mediate physiological processes. 
 
 
4.2 Understanding the role of copper in prion conversion and susceptibility with a special 
focus on the fifth copper binding site. 
 
Despite numerous investigations, the conversion mechanism(s) leading to PrPSc formation and 
transmission remain unclear. NMR-based studies on both Hu and MoPrP structured domains 
have proposed a role of the β2-α2 loop as dynamic “switch” element able to modulate prion 
conversion and susceptibility of a given specie to TSE [122]. However, the structural 
rearrangements occurring at the N-terminal region have not yet been clarified due to its intrinsic 
disorder. As already discussed, the N-terminal domain features several copper binding sites; 
although there is some contention, the non-OR copper binding site is the highest affinity site for 
copper in PrPC [233, 234]. This region attracted interest because of its location adjacent to the 
palindromic motif sequence AGAAAAGA. This regional proximity raised the question whether 
copper bound to the non-OR site may have an impact on prion conversion. Indeed, the 
interaction of copper with a peptide including both the non-OR and the palindromic motif has 
been shown to induce β-sheet formation and aggregation of this segment [234, 235]. Further in 
vivo findings have supported the idea that the region encompassing residues 90-125 is involved 
in prion generation. Moreover, in a previous X-ray study from our laboratory it has been found 
that this palindromic domain can initiate β-sheet enrichment when HuPrP is crystallized in 
complex with a Nanobody [40], suggesting that the segment 90-127 may act as alternative N-
terminal switch for prion conversion. 
In this work, we provide structural and biological evidence that the non-OR region may have 
pivotal biological implication in prion formation and susceptibility to prion diseases. 
In the WT HuPrP Cu(II) and Cu(I) are anchored to His96 and His111 only at pH 5.5, while at 
pH 7 copper at both oxidative states is coordinated by His111. Conversely, in the mutants (i.e. 
 
_____________________________________________________________________________ 
 
81
the GSS-causing Q212P and P102L mutants and the artificial H96Y mutation) copper is bound 
only to H111 independently of the pH value. 
The MD simulations propose a model whereby the molecular switch between the 2His and 
1His systems (i.e. copper bound to H96 and H111, or only to H111, respectively) may have 
structural implications. The 1His coordination seems to favor β-sheet enrichment in the region 
encompassing residues 106-117. At this stage it is unclear how this early β-sheet conversion 
may drive a complete structural conversion to PrPSc, but the new structural rearrangements 
occurring at the palidromic motif might serve as a nucleus for the association of intermolecular 
β-strands. 
To interpret these structural clues in the context of more relevant physiological implications, 
we used ScN2a and N2a cells transiently expressing 3F4-MoPrP with the substitutions of his 
residues by tyr residues at N-terminal copper binding sites (OR and non-OR regions) to abolish 
the binding of copper in these regions. We found that prion replication was not affected by the 
lack of each histidine in the OR region, in agreement with previous studies, confirming that the 
deletion of an octapeptide repeat did not lead to prion disease [236]. Conversely, His to Tyr96 
substitution removes one crucial copper ligand, thus it may allow to link the effect caused by 
altered copper coordination with prion conversion. The expression of H96Y mutant highly 
promotes prion conversion in ScN2a cells and spontaneously generated PrPres together with 
intracellular MoPrP accumulation in N2a cells. We hypothesize that the non-OR copper-binding 
site at H96 is much more important for both PrPC function, as shown by the higher affinity for 
copper binding compared to the OR region [173], and prion propagation and infectivity [237]. 
Residue H96 is located in a PrPSc region that is partially resistant to PK, thus copper bound to 
H96 may have a role during PrPSc formation even in the absence of the OR region [238]. Based 
on our findings, we propose that the H96Y mutant may act as other pathogenic mutations 
located in both N- and C-terminal domains (e.g. P102L and Q212P), causing spontaneous prion 
conversion. Our analysis shows that H96Y mutation induces PrPC accumulation in the acidic 
endosomal compartments, as observed for other disease-linked mutations [78]. The pH change 
from neutral to acidic values has been proposed to trigger the PrPC conformational conversion 
and a change in the balance of distinct internalization mechanisms may promote PrPSc 
replication by diverting the protein to distinct intracellular compartments and inhibiting the 
cellular protein quality control systems [239]. We report here enhanced PK-resistance of the 
H96Y mutant when expressed in ScN2a cells and its ability to generate de novo PrPres in N2a 
cells.  
These findings propose a pivotal role for non-OR region as critical molecular switch for prion 
conversion (Figure 4.2). We therefore argue that copper bound to the non-OR region may 
stabilize this segment when coordinated by four amino acid copper centers (i.e. His96, His111), 
preventing misfolding events through transient short and long-range interaction contacts 
between the 90-127 residues and the C-terminal structured domain. Copper acts as a key 
modulator of this process since its absence from PrPC side promote prion conversion, as 
observed in WT ScN2a cells treated with a copper chelator. 
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Figure 4.2. Model for the non-OR region molecular switch at acidic pH. PrPC coordinating copper with one 
His residue in the non-OR region is more prone to the conversion at acidic pH condition. As PrPSc model we used 
the HET-s(218-289) 2KJ3 PDB structure. 
 
 
After assessing the role of the non-OR region in the prion conversion, we expanded our 
knowledge on Cu(II) coordination in different mammalian PrPC. We analyzed the Cu(II) 
coordination in both prion resistant (OpPrP and OvPrP ARR) and susceptible (BvPrP and OvPrP 
VRQ) PrPC species. 
In the OpPrP and OvPrP ARR, we found that four residues are surrounding the copper ions, 
while in BvPrP, OvPrP VRQ and in HuPrP with the pathological point mutations Q212P and 
P102L the copper is coordinated by three residues. 
Based on our data, we prepared two models for Cu(II) coordination in both prion resistant and 
susceptible species (Figure 4.3).  
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Figure 4.3. Copper coordination models in the non-OR region of the resistant and susceptible species. 
Schematic representations of copper coordination (A) type-1 and (B) type-2. Blue spheres identify nitrogen atoms, 
red spheres are oxygen atoms and yellow spheres encode for sulfur atoms. Gray and white spheres represent carbon 
and hydrogen atoms, respectively. 
 
 
Type-1 Cu(II) coordination display a closed non-OR region conformation associated with less-
susceptible species likely because of higher stability of the PrPC structure. Instead, in type-2, a 
water molecule enters the coordination shell, thus leading to a less structured and solvent 
exposed non-OR region. The more opened conformation of the non-OR region in the type-2 
might render the overall PrPC structure more flexible; therefore we correlate this with higher 
susceptibility to prion diseases. 
Our data highlighted how copper coordination in the non-OR copper binding site may explain 
the different susceptibility to TSE observed in these mammalian species. 
 
 
4.3 Conclusions 
 
The present thesis aims at characterizing the role of the PrPC N-terminal domain in regulating 
the physiological function of PrPC and its involvement in the prion conversion. 
The flexibility characterizing the unstructured domain qualifies PrPC as a partially unstructured 
protein. Important features of the protein N-terminus include the ability to interact with both 
metal ions and with protein ligands. 
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In this study we provide a structural and biological evidence that the non-OR region has a 
crucial role in promoting prion conversion. 
In particular, we have shown that a Cu(II) coordination displaying a closed non-OR region 
conformation is associated with less-susceptible species likely because of higher stability of the 
PrPC structure, while a less structured and solvent exposed non-OR region leads to a more 
opened conformation of the non-OR region that might render the overall PrPC structure more 
flexible. We finally correlate the copper coordination in the non-OR copper-binding site with the 
different susceptibility to TSE observed in these mammalian species (Figure 4.3). 
Moreover, we provide the first structural evidence that the N-terminal domain of PrPC interacts 
with NCAM through its FNIII1,2 domain. We found that this interaction is mediated by the 
segment from residues 23 to 50 including four positively charged residues (i.e. KKRPK) known 
to play a role in the PrPC endocytic trafficking and in its localization to lipid rafts [17, 230]. Our 
study suggests that the interaction between residues 23–50 and the NCAM fibronectin domain 
may determine the fate of PrPC in the cell surface raft domain. PrPC participates in the complex 
molecular networks and signaling mechanisms, both cell-intrinsic and cell-extrinsic, that 
influence cell fate and differentiation.  
In conclusion, in the present thesis we highlighted how the N-terminus of PrPC is involved in 
both metal binding and signaling transduction due to the presence of different epitopes engaged 
in the binding of metal ions as well as molecules involved in signaling mechanisms such as 
NCAM (Figure 4.4). 
 
 
Figure 4.4. PrPC interaction with copper ions and NCAM. PrPC interacts with copper ions through the 
octarepeats and non-octarepeats regions (segments in orange), and with the FNIII1,2 domains of NCAM via the 
PrPC 23-50 segment (in blue). Affinity constants are indicated.  
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APPENDIX I 
 
 
 
SUPPLEMENTARY RESULTS 
 
PROTEIN EXPRESSION AND PURIFICATION 
 
 
1. Prion proteins expression in LB medium. 
All MoPrP, HuPrP and other mammalian PrPs variants were cloned into plasmid pET11a. The 
recombinant proteins were produced in E. coli BL21(DE3) in LB medium. As a reference, here 
we showed results of the HuPrP23-231 WT only.  
Large scale protein expression was achieved using a 2 L bioreactor which allows an automated 
pH, stirrer, temperature and pO2 control. The characteristic fermentation plot of a E. coli 
BL21(DE3) culture grown in M9 MM is presented in Figure 1 B. As we can see from the pO2 
curve, bacteria consume oxygen intensively for about 6 hours after induction. The expression in 
bioreactor allows bacterial yield of 9-10 g/l of paste and a final OD600 nm of 7-8. On the basis of 
expression protocols already established in our laboratory, we confirmed that the PrP expression 
always results in the formation of insoluble inclusion bodies, even at low temperature and IPTG 
concentration (Figure 1 C). 
 
 
  
Figure 1: Large scale expression of WT HuPrP (23-231). 
(A) 10 L bioreactor station. (B) Fermentation plot of the 
protein of interest in M9 MM. pO2 is the curve of soluble 
oxygen in the medium. During the bacterial growth, it starts 
from 30-35% (exponential phase) until ~75% (plateau). The 
pH curve remains at physiological value thanks to the 
automated control with acidic and basic solutions. (C) 
Expression of HuPrP23-231 in E. coli BL21 (DE3), T0: 
before induction, T16: 16 hours after induction, IB: inclusion 
bodies.  
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2. FNIII1, FNIII2 and FNIII1,2 expression and solubility trials for NMR structural studies 
Small scale expression trials in M9 MM aimed at finding the conditions to increase the FNIII1, 
FNIII2 and FNIII1,2 expression and its solubility in E. coli BL21 (DE3). We evaluated the 
effect of growth temperature and the effect of IPTG concentration on the expression level at 
25°C, 30°C and 37°C (Figure 2). We observed that the protein expression results in the soluble 
fraction (data not shown). We concluded that FNIII1 can be highly and efficiently expressed in 
M9 MM at 30°C at IPTG concentration of 0.5-0.75 mM, while FNIII2 and FNIII1,2 at 30°C at 
IPTG concentration of 0.25 mM. Unfortunately, we experienced solubility problems with 
FNIII1, therefore we were not able to use it for NMR experiments. 
 
 
 
 
 
0.25 0.5 0.75 0.25 0.5 0.75[IPTG] mM
T0 ————T16————
0.25 0.5 0.75 0.25 0.5 0.75
30° 37° 30° 37°
————T16————T0
FNIII1 FNIII2A B
Figure 2: Small scale expression trials in 
M9 MM of E. coli BL21 (DE3) expressing (A) 
FNIII1, (B) FNIII2 and (C) FNIII1,2. Effect of 
the temperature on FNIII constructs expression 
level (50 ml colture grown for 16 hrs) and 
effect of IPTG concentration on expression 
level at 25°C, 30°C and 37°C. 
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3. Protein purifications and refolding 
The soluble FNIII2 for NMR studies contained an uncleavable Histag at the C-terminus and 
were purified using HIMAC. The protein was virtually pure after this purification step (Figure 3 
A). FNIII2 was assessed as a monodisperse peak using an analytical gel filtration column 
(Superdex 200-10/300), equilibrated in 25 mM NaOAc, 0.2 M NaCl, pH 6.0 (Figure 3 B). 
About the recombinant PrPs, the main advantages of the expression of prion proteins as 
insoluble inclusion bodies are the high levels of expression and the possibility to easily purify 
extremely pure proteins after the first purification step. However, inclusion bodies need to be 
solubilized in strong denaturant agents (such as GndHCl or urea) before use. Therefore, all the 
purifications were achieved in non-native condition due to the presence of 2-6 M GndHCl in the 
buffers. Another aspect limiting our work with proteins expressed as inclusion bodies is the 
refolding process. This step always resulted in protein precipitations (approximately 50% of the 
total amount of refolded protein), independently of PrPs or TEV protease, which required 
additional re-solubilization steps with GndHCl of protein precipitates and refolding. 
In Figure 3 D-F the purified proteins used for NMR and EXAFS experiments. 
  
 
_____________________________________________________________________________ 
 
88 
 
 
 
 
Figure 3. Protein purifications. (A) Above, Chromatographic plot of the purification of FNIII2 C-ter_HisTag by 
HisTrap column, and below the corresponding SDS-PAGE of the elution profile. Arrow indicates FNIII2. (B) 
Analytic gel filtration on FNIII2. The inset corresponds to the SDS-PAGE of FNIII2 corresponding of the 
monodispersed peak. (C) Above, Size exclusion chromatography profile, and below and SDS-PAGE of HuPrP(23-
231, M129). (D-F) SDS-PAGE of the purified proteins used for NMR and EXAFS experiments. 
  
	
	
9
19
26
A B
15-
25-
35-
40-
55-
70-
D
C
	
	
10
15
25
35
E
10
15
25
35
HuP
rP(2
3-1
44)
HuP
rP(2
3-1
44)
 _la
bel
ed
FN
III2
FN
III2
 lab
ele
d
F
 
_____________________________________________________________________________ 
 
89
EXAFS ANALYSIS 
 
Table S1. Structural parameters derived from the EXAFS analysis. Structural parameters detemined from the 
fit of the EXAFS data at the Cu K-edge of samples 1 to 14. N is the coordination number, R is the distance between 
the copper ion and the ligand, s2 is the Debye-Waller factor. Statistical errors are reported in parentheses. Codes 1 
to 14 correspond to the following samples: Cu(II) WT HuPrP(90-231) pH5.5 (1), Cu(II) WT HuPrP(90-231) pH 7.0 
(2), Cu(II) HuPrP(90-231, Q212P) pH 5.5 (3), Cu(II) HuPrP(90-231, Q212P) pH 7.0 (4), Cu(II) HuPrP(90-231, 
P102L) pH 5.5 (5), Cu(II) HuPrP(90-231, P102L) pH 7.0 (6), Cu(II) HuPrP(90-231, H96Y) pH 5.5 (7), Cu(II) 
HuPrP(90-231, H96Y) pH 7.0 (8), Cu(I) WT HuPrP(90-231) pH 5.5 (9), Cu(I) WT HuPrP(90-231) pH 7.0 (10), 
Cu(I) HuPrP(90-231, Q212P) pH 5.5 (11), Cu(I) HuPrP(90-231, Q212P) pH 7.0 (12), Cu(I) HuPrP(90-231, P102L) 
pH 5.5 (13), Cu(I) HuPrP(90-231, P102L) pH 7.0 (14). 
 
 
 
Cu(II) WT pH=5.5 (1) Cu(II) WT pH=7.0 (2) Cu(II) Q212P pH=5.5 (3) Cu(II) Q212P pH=7.0 (4) 
N R (Å) s2 (Å2) N R (Å) s2 (Å2) N R (Å) s2 (Å2) N R (Å) s2 (Å2) 
2 NHis 1.98(2) 0.006(3) 1 NHis 1.99(2) 0.006(3) 1 NHis 2.00(2) 0.007(3) 1 NHis 1.99(2) 0.007(3) 
2 O/N 1.98(2) 0.008(3) 3 O/N 1.99(4) 0.009(3) 3 O/N 1.99(2) 0.009(3) 3 O/N 1.99(3) 0.009(3) 
1 O 2.31(3) 0.013(4) 1 O 2.38(4) 0.012(4) 1 O 2.40(4) 0.013(4) 1 O 2.39(3) 0.012(4) 
1 S 3.25(4) 0.013(4) 1 S 3.37(4) 0.013(4) 1 S 3.47(4) 0.014(4) 1 S 3.45(4) 0.012(4) 
Cu(II) P102L pH=5.5 (5) Cu(II) P102L pH=7.0 (6) Cu(II) H96Y pH=5.5 (7) Cu(II) H96Y pH=7.0 (8) 
N R (Å) s2 (Å2) N R (Å) s2 (Å2) N R (Å) s2 (Å2) N R (Å) s2 (Å2) 
1 NHis 2.00(3) 0.006(3) 1 NHis 1.99(2) 0.006(3) 1 NHis 2.00(2) 0.007(3) 1 NHis 2.00(2) 0.008(3) 
 O/N 1.99(3) 0.008(3) 3 O/N 1.99(3) 0.009(3) 3 O/N 1.99(2) 0.009(3) 3 O/N 1.99(2) 0.008(3) 
1 O 2.34(4) 0.013(4) 1 O 2.38(3) 0.012(4) 1 O 2.40(3) 0.013(4) 1 O 2.39(3) 0.012(4) 
1 S 3.32(4) 0.013(4) 1 S 3.38(4) 0.013(4) 1 S 3.47(4) 0.014(4) 1 S 3.45(4) 0.013(4) 
Cu(I) WT pH=5.5 (9) Cu(I) WT pH=7.0 (10) Cu(I) Q212P pH=5.5 (11) Cu(I) Q212P pH=7.0 (12) 
N R (Å) s2 (Å2) N R (Å) s2 (Å2) N R (Å) s2 (Å2) N R (Å) s2 (Å2) 
2 NHis 1.98(2) 0.006(3) 1 NHis 1.98(2) 0.007(3) 1 NHis 1.99(2) 0.007(3) 1 NHis 1.99(2) 0.007(3) 
2 O/N 1.99(3) 0.009(3) 1 O/N 2.00(2) 0.009(3) 1 O/N 1.99(2) 0.009(3) 3 O/N 1.99(3) 0.009(3) 
1 O 2.32(4) 0.014(4) 1 S 2.27(4) 0.009(4) 1 S 2.28(4) 0.008(3) 1 S 2.27(3) 0.009(4) 
1 S 3.26(5) 0.013(4)          
Cu(I) P102L pH=5.5 (13) Cu(I) P102L pH=7.0 (14)   
N R (Å) s2 (Å2) N R (Å) s2 (Å2)       
1 NHis 2.00(2) 0.009(3) 1 NHis 1.99(2) 0.008(3)       
1 O/N 1.99(2) 0.009(3) 3 O/N 1.99(3) 0.009(3)       
1 S 2.28(4) 0.009(3) 1 O 2.29(3) 0.010(4)       
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Table S2. Structural parameters derived from the EXAFS analysis. Structural parameters determined from the 
fit of the EXAFS data at the Cu K-edge of Cu(II) HuPrP, Cu(II) OvPrP ARR, Cu(II) OpPrP, Cu(II) HuPrP Q212P, 
Cu(II) OvPrP VRQ, Cu(II) BvPrP. N is the coordination number, R is the distance between the copper ion and the 
ligand, σ2  is the Debye-Waller factor. Statistical errors are reported in parentheses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OvPrP ARR OpPrP 
N R (Å) σ2 (Å2) N R (Å) σ2 (Å2) 
1 NHis 1.98(2) 0.008(3) 1 NHis 1.98(2) 0.008(3) 
3 O/N 2.00(2) 0.006(3) 3 O/N 2.00(2) 0.009(3) 
1 O 2.32(5) 0.015(4) 1 O 2.28(5) 0.014(4) 
1 S 3.27(4) 0.009(4) 1 S 3.23(4) 0.009(4) 
2 C 2.86(4) 0.007(4) 2 C 2.87(4) 0.006(4) 
OvPrP VRQ BvPrP 
N R (Å) σ2 (Å2) N R (Å) σ2 (Å2) 
1 NHis 2.00(2) 0.008(3) 1 NHis 2.00(2) 0.008(3) 
3 O/N 1.99(3) 0.009(3) 3 O/N 1.99(2) 0.009(3) 
1 O 2.41(3) 0.010(4) 1 O 2.41(3) 0.009(4) 
1 S 3.26(4) 0.015(4) 1 S 3.26(4) 0.013(4) 
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Figure S1. Comparison between the Cu K-edge EXAFS spectra (red lines) of Cu(II) OvPrP ARR (A), Cu(II) 
OpPrP (B), Cu(II) OvPrP VRQ (C), and Cu(II) BvPrP (D) and theoretical curves (blue lines) calculated with the 
type-1 and type-2 copper coordination models.  
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APPENDIX II 
 
 
 
SUPPLEMENTARY MATERIALS AND METHODS 
 
1. STED nanoscopy experiments 
 
Note: STED microscopy was performed at the NanoBiophotonics Department (Max Plank 
Institute for Biophysical Chemistry, Göttingen, Germany) and analyzed by Dr. Ladan Amin. For 
this reason, the related Materials and Methods are presented in this separate section. 
 
Cell culture. P1-P2 FVB wt mice were sacrificed by decapitation in accordance with the 
guidelines of the Italian Animal Welfare Act. 
Immunostaining. Cells were fixed in 4% paraformaldehyde containing 0.15% picric acid in 
phosphate-buffered saline (PBS), saturated with 0.1 M glycine, permeabilized with 0.1% Triton 
X-100, saturated with 0.5% BSA (all from Sigma-Aldrich, St. Louis, MO) in PBS and then 
incubated for 1 h with primary antibodies followed by the 30 min incubation with secondary 
antibodies conjugated with STAR580 or STAR635P (Abberior, Göttingen, Germany). All 
incubations were performed at room temperature (20-22 °C). 
STED microscopy. 2-color STED microscopy was performed at the NanoBiophotonics 
Department (Max Plank Institute for Biophysical Chemistry, Göttingen, Germany) equipped 
with 561 nm and 640 nm pulsed excitation lasers, a pulsed 775 nm STED laser, and a 100x oil 
immersion objective lens (NA 1.4). 
 
 
2. Molecular Dynamics simulation on HuPrP WT 
 
Note: The simulation-based structural predictions were performed by Giordano Mancini 
(Scuola Normale Superiore, Pisa, Italy). For this reason, the related Materials and Methods are 
presented in this separate section. 
 
Two simulations of WT HuPrP(90-231) in complex with Cu(II) were performed in order to 
resemble experimental conditions either at pH 5.5 or pH 7.0. Based on experimental results, in 
the simulation resembling pH 5.5 (hereafter termed 2His) both H96 and H111 were bound to 
Cu(II), while at pH 7.0 (hereafter termed 1His) only H111 was bound to the metal. Starting 
coordinates of HuPrP(90-231) were obtained from the 1QM1 PDB structure [25]. Missing 
hydrogen atoms were added by MolProbity [254] and protonation states counter-checked with 
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H++ code [255]. To model the binding of Cu(II) in the active site a set of harmonic springs was 
used to enforce copper-ligand distances [256]. Bond lengths of the springs were based on 
EXAFS data and set to 1.98 Å for the Nδ imidazole atoms in H96 and H111, to 1.98 Å for the 
amide oxygen in Q98 and to 3.25 Å for the S atom in M109. The systems were modeled using 
the AMBER99SB-ILDN* all-atom force field[257] implemented in the GROMACS MD 
package version 4.6.5 [258]. The protein was immersed in a rhombic dodecahedron box with a 
minimum distance of 2.5 nm from the box edges; a long distance from the box edges was used 
to take into proper account the flexibility of HuPrP(90-231). The resulting system was 
composed of 2192 protein atoms, 54873 TIP3P [259] water molecules, 1 Cl- ion for a total of 
166812 atoms. Electrostatic interactions were accounted by means of the Particle Mesh Ewald 
method (PME) using a cutoff of 1.5 nm for the real space and Van der Waals interactions [260]. 
The LINCS algorithm was used to constrain bond lengths and angles[261], with the exception of 
Cu(II)-protein bonds. Relaxation of solvent molecules and Cl- ion was initially performed 
keeping solute atoms restrained to their initial positions with a force constant of 1000 kJ/(mol • 
nm2), for 3.0 ns in a NPT ensemble and using an integration time step of 1.0 fs. Then, the system 
was simulated for 5 ns while using a force constant of 1000 kJ/(mol • nm2) for bonds involving 
Cu(II) to force the active site residues in the desired position. At this point H111 was freed to 
create the 1His system and after this step two separate simulations were carried out. The two 
systems were carried again to 0 K, the force constants in the active site changed to 100 kJ/(mol • 
nm2) and then heated again to 298.15 K. The two systems were then simulated for 150 ns in a 
NVT ensemble with a time step of 2.0 fs and the neighbor list was updated every 10 steps. 
Temperature was kept constant using the velocity rescale method with a coupling constant of 0.1 
ps during sampling [262]. Structures were clustered using backbone atoms and the GROMOS 
method [263]. A total of 15000 frames from each simulation were selected with constant pace of 
10 ps and a Root Mean Square Deviation (RMSD) threshold of 0.30 nm; only the positions of 
Cα carbon atoms were used for clustering. Two residues were considered to be bound by a 
hydrogen (H) bond in a given frame if the H-acceptor distance was below 0.375 nm and the 
acceptor – donor– H angle was below 40.0°. Two residues are connected by a salt bridge if the 
nitrogen-oxygen distance is below 0.4 nm in a given frame. All analyses were carried out with 
standard tools present in the GROMACS MD package v. 4.6.5 or with in-house written codes, 
except for secondary structure assignment which was performed with DSSP [264]. Figures were 
produced with Chimera 1.10 software. 
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